

# Index

Note: Page references in *italics* refer to Figures; those in **bold** refer to Tables and Boxes

- ablative procedures
  - in CIN management 190
- abnormal fetal karyotype
  - as risk for RPL 133
- abnormal menstrual bleeding 13–20 *see also* heavy menstrual bleeding (HMB)
  - background 13–14, **13**
  - case scenario 13
- abnormal placentation
  - suspected
    - tests for 552–3
- abnormal uterine bleeding (AUB)
  - defined 13
  - FIGO on 13
- abortion
  - failed 26–7
  - induced 21–32 *see also* induced abortion
  - medical evaluation prior to 22
  - pregnancies ending in 89
  - spontaneous
    - incidence of 33
- abuse
  - substance *see* substance abuse
- acanthosis nigrans (AN)
  - PCOS and 122–3, 122
- acceleration
  - defined **498**, 499, **499**
  - in FHR
    - physiology of 502
- ACCP
  - on VTE prevention during pregnancy 359, 361
- ACE inhibitors *see* angiotensin-converting enzyme (ACE) inhibitors
- acne
  - isotretinoin for 207
  - PCOS and 122, 122
- ACOG *see* American College of Obstetricians and Gynecologists (ACOG)
- ACOG/SMFM Obstetric Care Consensus 569
- acquired cardiac disease 267–73
  - antepartum management of 268–9
  - case scenario 267–8
  - causes of 268
  - clinical questions 268–73
- acquired valvular lesions
  - in pregnant women
    - causes of 268
- Actim PROM 398
- active labor
  - centimeter progression during 570
  - initiation of 570
- active management of risk in pregnancy at term (AMORIPAT) 528
- active management of third stage of labor (AMTSL) 569
  - benefits of 576–7, **576**
  - described 576–7, **576**
  - oxytocin in 576–9, **576**, 578 *see also* oxytocin, in AMTSL
  - TXA in 578
- acupuncture
  - in endometriosis pain management 79
  - in HG management 228
  - in post-term pregnancy management 436
- acute anemia
  - HMB and 15
- acute glomerulonephritis
  - pre-eclampsia vs. **292**
- acute phase arrest
  - diagnosis of 570, **570**
- acyclovir
  - for recurrent HSV infection 58, **58**
- adenocarcinoma-in-situ (AIS)
  - case scenario 189
  - progression to cancer
    - risk factors for 192
  - recurrence of
    - risk factors for 192
- adenomyomectomy
  - in adenomyosis pain management 81
- adenomyosis 75–87
  - background 76

- case scenario 75
- clinical questions 76–83
- diffuse 76
- evaluation for 77–8
- focal 76
- infertility due to 76
- pain symptoms of
  - management of 79–82
- risk factors for 76
- search strategy 76
- symptoms of 76
- adjuvant analgesics
  - for CPP 52, **53**
- AEDs *see* antiepileptic drugs (AEDs)
- AF *see* amniotic fluid (AF)
- age
  - gestational
    - large for 451–2
  - maternal *see* maternal age
- Agency for Healthcare Research and Quality (AHRQ) 6
- aging
  - ovarian
    - menopause and 156
- AHRQ *see* Agency for Healthcare Research and Quality (AHRQ)
- AIS *see* adenocarcinoma-in-situ (AIS)
- alcohol use
  - preconception care related to 207–8
- alkaline hematin
  - for vaginal bleeding 66
- amenorrhea 109–16 *see also specific types*
  - background 109
  - case scenario 109
  - causes of 109–13
  - classification of 109
  - clinical questions 109–13
  - defined 109
  - endocrine disorders and 110–11
  - evaluation of 109–10
  - hypothalamic 111
  - menopause and 112–13
  - menstrual physiology in 110
  - mosaicism and 111
  - outflow tract abnormalities resulting in 110
  - PCOS and 112
  - pituitary disorders and 111–12
  - primary *see* primary amenorrhea
  - pure gonadal dysgenesis and 111
  - secondary *see* secondary amenorrhea
  - treatment of 113
- American College of Obstetricians and Gynecologists (ACOG)
  - on aneuploidy screening 213
  - on diagnostic tests for RPL 132
  - on HG management 229
  - on second stage of labor 569
  - on VTE prevention during pregnancy 359
- American Society of Reproductive Medicine (ASRM)
  - endometriosis staging system of 75
- amitriptyline
  - for CPP 52, **53**
- amniocentesis
  - in NTDs detection 220
  - for pregnant women at high risk for aneuploidy 218–19
- amnioreduction (AR)
  - in polyhydramnios management 445–6
- amniotic fluid (AF)
  - excessive *see* polyhydramnios
- amniotic fluid (AF) abnormalities
  - perinatal outcome related to
    - ultrasound in detection of 444, **444**
- amniotic fluid (AF) volume
  - background 443
  - described 443
  - disorders of 443–9 *see also* polyhydramnios
    - case scenario 443, 447
    - clinical questions 443–7
- amniotomy
  - in cervical ripening **531**, 532
- AmniSure ROM Test 398
- AMORIPAT *see* active management of risk in pregnancy at term (AMORIPAT)
- AMTSL *see* active management of third stage of labor (AMTSL)
- AN *see* acanthosis nigrans (AN)
- analgesics
  - for CPP 52, **53**
- anemia
  - acute
    - HMB and 15
  - blood loss
    - management of 336, **336**
- anesthesia/anesthetics
  - for cesarean delivery in obese women 595–6
  - conduction
    - labor courses related to 537
- aneuploidy
  - pregnant women at risk for
    - cfDNA analysis for 213–14
  - prenatal diagnosis for 213–23 *see also* prenatal diagnosis
    - screening for 213
- angiotensin-converting enzyme (ACE) inhibitors
  - fetal effects of 238, **239**, **238**
- antenatal corticosteroids 2
  - in reducing morbidity and mortality from preterm birth 388, 390, 391
- anteartum factors
  - impact on uterine rupture 420
- anteartum hemorrhage (APH) 407–17
  - background 407
  - case scenario 407, 411, 413
  - causes of 407
  - clinical questions 407–11
  - defined 407
  - management of 407
  - prevalence of 407
  - undetermined/unexplained
    - expectant management for 413
- anteartum/intrapartum fetal surveillance 495–511
  - introduction 495
- anti-androgens

- in PCOS management 124
- anxiolytics
  - during pregnancy 206
- antibiotic prophylaxis
  - for cesarean delivery in obese women 594–5
- antibiotics
  - prophylactic *see* prophylactic antibiotics
- antibody screen
  - in women with EP 42
- anticoagulant therapy
  - for RPL 138–40, 139
- antidepressant(s)
  - breastfeeding while taking 380
  - discontinuing
    - among women who wish to or have recently conceived 377–8
  - during pregnancy 207
- antiemetics
  - in pregnancy **228**, 229
- antiepileptic drugs (AEDs)
  - during pregnancy
    - concerns related to 316–17
    - pharmacokinetic changes related to 316
- antifibrinolytics
  - for HMB 15–16
- antihypertensive agents
  - in preconception care 204–5
- antioxidants
  - in FGR management and prevention 457
- antiphospholipid antibodies
  - pre-eclampsia and 257
- antiphospholipid syndrome (APS) 135–7, 138
  - β-hCG for 325–33
    - case scenarios 131, 325–6
  - catastrophic *see* catastrophic antiphospholipid syndrome (CAPS)
  - classification criteria for 327–8, **327**
  - clinical presentation of 326–7
  - clinical questions 326–30
  - definite 327–8, **327**
  - diagnosis of 326
  - introduction 325
  - obstetric
    - case scenario 325
  - possible or probable 325–6, 328
  - during pregnancy
    - complications related to 326–7
    - considerations related to 330–1
    - management of 136–41, 138, **139**, **140**, 328–9
    - “refractory obstetric”
      - management of 329–30
  - as risk factor for RPL 133–4
  - thrombotic
    - case scenario 325
- antipsychotics
  - during lactation 380–1
  - during pregnancy 206
- antithrombin deficiency (ATD)
  - during pregnancy 356, **356**, **357**
- aortic disease
  - congenital
    - in pregnancy 276
- aortopathies
  - in pregnancy 275
- APH *see* antepartum hemorrhage (APH)
- appendicitis
  - possible
    - exploratory surgery for 372
    - in pregnancy 372
  - in pregnancy 369–73
    - background 369–70
    - clinical questions 370–3, **370**, **371**
    - delay in treatment of 372–3
    - diagnosis of 370–2, **370**, **371**
    - maternal and fetal risks associated with 372–3
- APS *see* antiphospholipid syndrome (APS)
- AR *see* amnioreduction (AR)
- Arias–Stella reaction 36
- aromatase inhibitors
  - in endometriosis pain management 78–9
  - for unexplained subfertility 147–8
- arrest of labor
  - defined 535
- arterial ligation
  - in PPH management 549
- artificial valves
  - during pregnancy 270–1
- ARTs *see* assisted reproductive technologies (ARTs)
- ASDs *see* atrioventricular septal defects (ASDs)
- Asherman syndrome 550
- aspiration
  - vacuum
    - induced abortion by 23, 24
- aspirin
  - for hereditary thrombophilias 139
  - low-dose
    - in FGR management and prevention 457
    - in reducing risk of pre-eclampsia 257
  - for patients with RPL and APS 136, **139**
- ASRM *see* American Society of Reproductive Medicine (ASRM)
- assisted reproductive technologies (ARTs)
  - EP related to 33, 35
  - heterotopic pregnancy and 33
  - twins after 467
  - zygotic splitting after 467
- asthma 247–53
  - background 247
  - case scenario 247
  - clinical questions 247–51
  - general search strategy 247
  - pregnant women with
    - agents impacting outcomes of 249–51, **250**
    - congenital anomalies 248, **248**
    - fetal outcomes related to 247–8, **248**
    - management of 249–51, **250**
    - outcomes related to 248–51, **250**
    - risk factors related to 247–8, **248**

- antiphospholipid syndrome (APS) (*continued*)
  - stillbirth related to 248, **248**
- Atad double-balloon device
  - in cervical ripening 532
- ATD *see* antithrombin deficiency (ATD)
- atrioventricular septal defects (ASDs)
  - in pregnancy 273, 274
- AUB *see* abnormal uterine bleeding (AUB)
- augmentation of labor 527–37
  - background 534–5
  - case scenario 534
  - clinical questions 535–7
  - impact on uterine rupture 422, 423–6
- auscultation
  - intermittent FHR
    - vs.* randomized trials of EFM 495
- autopsy
  - for stillbirth 481–2
- balloon catheters
  - transcervical
    - in cervical ripening **531**, 532
- balloon tamponade
  - in PPH management 549
- barrier methods
  - in contraception 94
- baseline
  - defined 497, **498**, **499**
- baseline FHR
  - defined 497, **498**, **499**
  - physiology of 502
- bazedoxifene (BZA)
  - in menopause 158–9
- bed rest
  - in preterm labor management 392
- benzodiazepine(s)
  - during lactation 381
  - during pregnancy 206–7
- beta-agonists
  - inhaled
    - impact on pregnancy women with asthma **250**, 251
- β-hCG
  - measurements of
    - in EP 33
- beta subunit of human chorionic gonadotropin (β-hCG) *see* β-hCG
- bimanual uterine compression
  - in PPH management 548–9
- biophysical profiles (BPPs)
  - in antepartum surveillance of growth-restricted fetuses
    - perinatal outcomes of 453
- bipolar I disorder
  - risk factors for 378
  - symptoms of 378
- birth(s)
  - cesarean *see also* cesarean delivery
    - preterm 40
    - TOL after previous 419
  - multiple 467–77 *see also* multiple pregnancies and births
  - premature
    - defined 397
    - preterm *see* preterm birth
    - vaginal *see* vaginal birth
- birth control
  - methods of 89
- birthweight
  - low *see* low-birthweight (LBW) infants
  - very low *see* very low-birthweight (VLBW) infants
- birthweight discordance
  - defined 472
  - in multiples 472
- Bishop score
  - modified 530, **530**
- bleeding *see also* hemorrhage
  - menstrual *see* menstrual bleeding
  - postpartum 545–57 *see also* postpartum hemorrhage (PPH)
  - vaginal *see* vaginal bleeding
  - in von Willebrand disease
    - management of 338–9, **338**
- blood loss anemia
  - management of 336, **336**
- blue cohosh
  - in post-term pregnancy management 436
- B-Lynch uterine compression suture
  - in PPH management 549, 550
- BMI *see* body mass index (BMI)
- body mass index (BMI)
  - cesarean delivery by women with high 593
  - impact on emergency contraception 94
  - impact on uterine rupture 420–1
  - in pregnant women 569, **571**
- bone loss
  - menopause and 158
- BPPs *see* biophysical profiles (BPPs)
- breastfeeding
  - antidepressant use while 380
  - psychiatric illness in women who are
    - medication concentration in breast milk 380–1
- breast milk
  - medication concentration in 380–1
- breech presentation
  - delivery with 521
  - in later third trimester
    - risk factors for 521
- breech vaginal delivery
  - cesarean delivery *vs.*
    - for third trimester malpresentation 521–2
- bulimia nervosa
  - HG related to 225
- “bundle”
  - defined 563
- BZA *see* bazedoxifene (BZA)
- cancer(s) *see also specific types*
  - AIS progression to
    - risk factors for 192
  - cervical 165–72
  - cervical dysplasia progression to
    - risk factors for 192

- CIN progression to
  - risk factors for 192
  - endometrial 181–8
  - vaginal 173–80
  - vulvar 173–80
  - vulvovaginal 174–5, **174**
- cannabis use
  - during pregnancy 207–8
- CAPS *see* catastrophic antiphospholipid syndrome (CAPS)
- carbimazole
  - for Graves' disease in pregnancy 309, **310**
- cardiac disease
  - acquired 267–73 *see also* acquired cardiac disease
  - cyanotic
    - obstetric and fetal risks in women with 275
  - epidemiology of 265–6
  - preconception care in management and prevention of 205
  - preconception counseling for women with 268
  - pregnant women with
    - antibiotic prophylaxis for 272
    - risk assessment models for 266–7, **266**
  - WHO classification system on 267
- cardiomyopathy
  - dilated 279
  - hypertrophic 278
  - peripartum 277–80 *see also* peripartum cardiomyopathy (PPCM)
  - in pregnancy 277–80
    - case scenario 277
    - delivery and monitoring methods for 280
    - postpartum care for 280
    - risk factors for 279
  - restrictive 278–9
  - traditional forms of
    - management of 279–80
  - vs.* PPCM 278–9
  - types of 278–9
- cardiopulmonary arrest 565–6
  - case scenario 565
  - in pregnant women
    - immediate *vs.* delayed perimortem/resuscitative cesarean section for 565–6
- cardiovascular disease (CVD) 265–86 *see also specific diseases, e.g.,*
  - congenital heart disease
  - acquired cardiac disease 267–73
  - cardiomyopathy 277–80
  - congenital heart disease 273–7
  - contraceptive use and 92
  - introduction 265–7
  - long-term maternal risk of
    - postpartum counseling related to 261–2
  - menopause and 158
  - PPCM 277–80
- “care bundle”
  - defined 563
  - in management of VTE events in pregnant women admitted to hospital 562–5
- CARPREG risk prediction score
  - for cardiac event during pregnancy 266, **266**
- catastrophic antiphospholipid syndrome (CAPS)
  - classification criteria for 328, **328**
  - described 327
  - during pregnancy
    - management of 330
- CCT *see* controlled cord traction (CCT)
- CDC *see* Centers for Disease Control and Prevention (CDC)
- CD4 counts
  - low
    - vulvovaginal cancers related to 174
- cell-free fetal DNA (cfDNA) analysis
  - for pregnant women at risk for aneuploidy 213–14
  - in Trisomy 21 and Trisomy 18 detection 213–14
- Centers for Disease Control and Prevention (CDC)
  - Preconception Health and Health Care Initiative of 201, 202
  - USMEC of 92
- central nervous system (CNS)
  - in CPP 50–1
- cephalic presentation
  - ECV in effort to turn fetus into 521
- cervical cancer 165–72
  - background 165, 165
  - case scenario 165
  - causes of 165
  - clinical presentation of 165
  - clinical questions 166–9
  - early-stage
    - treatment of 168–9, **169**
  - HPV and 165, 167
  - incidence of 165
  - prevalence of 165
  - risk factors for 166–7, **166**
  - squamous cell carcinoma 165
  - staging of 168–9, **169**
  - symptoms of 165
  - treatment of
    - stage-related 168–9, **169**
  - types of 167
- cervical cerclage
  - PPROM management related to 402
- cervical dysplasia 189–95 *see also* cervical intraepithelial neoplasia (CIN)
  - background 189
  - case scenario 189
  - causes of 189
  - clinical questions 189–93
  - defined 189
  - general search strategy 189–90
  - management of
    - in pregnant patients 193
    - risks of preterm delivery after 192–3
  - prevention of
    - HPV vaccines in 191–2
  - progression to cancer
    - risk factors for 192
  - recurrence of
    - risk factors for 192
  - risk factors for 191
- cervical ectopic pregnancy (EP)

- cervical ectopic pregnancy (EP) (*continued*)
  - local therapy in 42
- cervical injury
  - induced abortion and 25–6
- cervical intraepithelial neoplasia (CIN) 189–95 *see also* cervical dysplasia
  - AIS-related
    - prevalence of 190–1
  - categories of 190
  - clinical questions 189–93
  - defined 189
  - detection of
    - diagnostic tests vs. cervical cytology in 167–8
  - HPV and 165, 167, 189–95 *see also* human papillomavirus (HPV)
  - prevention of
    - HPV vaccines in 191–2
  - progression to cancer
    - risk factors for 192
  - recurrence of
    - risk factors for 192
  - risk factors for 191
  - treatment of
    - ablative procedures in 190
    - CKC in 191
    - costs related to 190
    - cryotherapy in 191
    - excisional procedures in 191
    - laser ablation in 191
    - laser conization in 191
    - LEEP in 191
    - LLETZ in 191
    - risks of preterm delivery after 192–3
- cervical ripening
  - described 531
  - methods of 531–3, **531**
- cesarean birth
  - preterm
    - uterine rupture related to 420
  - TOL after previous 419
- cesarean delivery
  - BMI risks related to 593
  - breech vaginal delivery *vs.*
    - for third trimester malpresentation 521–2
  - complications following 593
  - induction of labor and 528–9
    - oxytocin related to 533–4
  - maternal–fetal complications of 585, **586**
  - in obese women 593–9
    - anesthesia considerations 595–6
    - antibiotic prophylaxis for 594–5
    - case scenario 593
    - clinical questions 593–7
    - LMWH for 596–7
    - technical surgical aspects at 594
    - thromboprophylaxis for 596–7
  - for pregnant women with cardiopulmonary arrest 565–6
  - prevalence of 583
  - prophylactic induction of labor for fetal macrosomia in
    - decreasing risk for 458, 460
  - in shoulder dystocia prevention 460, **460**
  - technical surgical aspects at 594
  - vacuum extraction at
    - safety considerations 587
  - vaginal birth after 419–30 *see also* vaginal birth after cesarean (VBAC) delivery
- cfDNA *see* cell-free fetal DNA (cfDNA) analysis
- chlamydia
  - clinical presentations of 55–6
  - diagnosis of 56–7
  - treatment of 57–8
- cholecystectomy
  - laparoscopic
    - for cholelithiasis in pregnancy 366–7
  - open
    - for cholelithiasis in pregnancy 366–7
- cholelithiasis
  - described 365
  - in pregnancy 365–7
    - clinical questions 365–7
  - described 365
  - diagnosis of 365–6
  - management of 366–7
- chorionic villous sampling (CVS)
  - for pregnant women at high risk for aneuploidy 218
- chromosome microarray analysis
  - in fetal anomalies diagnostic testing 487–8
  - for pregnant women at high risk for aneuploidy 219
- chronic diseases
  - management of
    - medications in 206–7
    - preconception care in 203–6
- chronic hypertension 258
  - preconception care for women with 204–5
- chronic kidney disease (CKD)
  - classification of 288–9, **288**
  - in pregnant women 287–96
    - background 288–90, 288–**90**
    - considerations 288–90, 288–**90**
    - impact of 289, **289**
    - management of 290–4
    - perinatal morbidity and mortality associated with 287
    - prevalence of 287
- chronic pelvic pain (CPP) 49–54
  - causes of
    - laparoscopy in identifying 51–2
  - clinical questions 50–2
  - CNS in 50–1
  - defined 49
  - general search strategy 50
  - initial consultation influencing 51
  - management of 52, **53**, 53
    - consensus on approach to 49–50
  - musculo-skeletal abnormalities in women of reproductive age
    - with 51
  - presentation of 49
- chronic salpingitis

- EP and 35
- cigarette smoking
  - during pregnancy *see* smoking
- CIL *see* complete inguinofemoral lymphadenectomy (CIL)
- CIN *see* cervical intraepithelial neoplasia (CIN)
- CIN 1
  - described 190
- CIN 2
  - described 190
  - recurrence risk and progression to cancer in women 192
- CIN 3
  - described 190
  - recurrence risk and progression to cancer in women 192
- CKC *see* cold knife conization (CKC)
- CKD *see* chronic kidney disease (CKD)
- clinical scoring systems
  - types of 561, **564**
- clomiphene citrate
  - for unexplained subfertility 146–7
- CMV *see* cytomegalovirus (CMV)
- CNS *see* central nervous system (CNS)
- Cochrane Collaboration 2, 5, **5**
- COCs *see* combined oral contraceptives (COCs)
- cognition
  - menopause effects on 158
- cognitive decline
  - menopause and 158
- cold knife conization (CKC)
  - in CIN management 191
- Collaborative Perinatal Project 569
- Collaborative Review of Sterilization (CREST) 90
- colpocleisis
  - in uterine prolapse management 102–3
- combined first and second trimester screening
  - for pregnant women with low or average risk for aneuploidy
    - in Trisomy 21 and Trisomy 18 detection 215–16, **215**
- combined oral contraceptives (COCs)
  - in endometriosis pain management 78
  - for HMB 16, **17**
  - in PCOS management 123–4
- complementary and alternative medicine
  - in post-term pregnancy management 435–6
- complete inguinofemoral lymphadenectomy (CIL)
  - in early-stage vulvar cancer management 175–6
- compression sutures
  - in PPH management 549–50, 550
- computed tomography (CT)
  - in appendicitis in pregnancy 371–2, **371**
- computed tomography pulmonary angiogram (CTPA)
  - for VTE in pregnancy 561, **563**
- conception(s)
  - DZ 467–8
  - MZ 467–8
  - retained products of
    - induced abortion and 26
- condoms
  - in contraception 94
- conduction anesthesia
  - labor courses related to 537
- Confidential Enquiries into Maternal Death 595
- congenital anomalies
  - oligohydramnios 488
  - single umbilical artery 488
  - stillbirth related to 490
  - in twins 488
  - in women with asthma 248, **248**
- congenital aortic disease
  - in pregnancy 276
- congenital heart disease 273–7
  - clinical questions 273–7
  - preconception care in management and prevention of 205
  - in pregnant women
    - antepartum management for 273
    - case scenario 273
    - maternal risks associated with 274–5
    - obstetric, fetal, and neonatal risks associated with 275–6
    - postpartum care for 277
    - preferred labor and delivery methods for 276
    - recurrence risk for subsequent child 273–4
- congenital pulmonary airway malformation (CPAM)
  - clinical questions 514–18
  - defined 513
  - diagnosis of
    - prognosis related to 517–18
  - hydrops fetalis with 513–19
    - case scenario 513–14, 514, 515
  - incidence of 513
  - prognosis of 513
  - treatment of 514, 515
    - in-utero 518
  - types of 518
- conjoined twins 467
- Consortium on Safe Labor (CSL) 569
- contingent screening
  - for pregnant women with low or average risk for aneuploidy
    - in Trisomy 21 and Trisomy 18 detection 216
- contraception 89–97 *see also* contraceptive use
  - background 89
  - barrier methods 94
  - case scenario 89, 94–5
  - clinical questions 89–93
  - effectiveness of
    - determinants of 90–1, **91**
  - emergency 94
  - general search strategy 90
  - LARC methods 89, 92
  - non-LARC methods 92–3
- contraceptive(s)
  - combined oral *see* combined oral contraceptives (COCs)
  - oral
    - in endometriosis pain management 78
    - risk factors associated with 92
- Contraceptive Choice Project 89
- contraceptive methods *see also specific types*
  - after induced abortion 27–8
- contraceptive use *see also* contraception
  - cardiovascular disease and 92
  - medical eligibility criteria for 91–2



- contraceptive use *see also* contraception (*continued*)
  - smoking and 92
  - unintended pregnancy during 91, **91**
- controlled cord traction (CCT)
  - in third stage of labor **576**, 577
- “Core Principles and Values of Effective Team-Based Health Care,” 559
- corticosteroids
  - antenatal 2
    - in reducing morbidity and mortality from preterm birth 388, 390, 391
  - in HG management 230
  - inhaled
    - impact on pregnant women with asthma 249–51, **250**
  - in PPROM management 399–400
- Coumadin
  - during pregnancy 206
- Council on Patient Safety in Women’s Healthcare 563
- counseling
  - fertility desires–related 90
  - on long-term health risks associated with PCOS 125–6, **126**
  - postpartum
    - on long-term maternal risk of CVD 261–2
  - preconception
    - for women with cardiac disease 268
    - for women with diabetes 203–4
  - pregnancy spacing and limiting–related 90
  - prior to induced abortion 22
  - sterilization methods–related 90
- CPAM *see* congenital pulmonary airway malformation (CPAM)
- CPP *see* chronic pelvic pain (CPP)
- CREST *see* Collaborative Review of Sterilization (CREST)
- cryotherapy
  - in CIN management 191
- CSL *see* Consortium on Safe Labor (CSL)
- CT *see* computed tomography (CT)
- CTPA *see* computed tomography pulmonary angiogram (CTPA)
- cultoplasty
  - McCall
    - in pelvic organ prolapse management 103
- CVD *see* cardiovascular disease (CVD)
- CVS *see* chorionic villous sampling (CVS)
- cyanotic heart disease
  - obstetric and fetal risks in women with
    - oxygen saturation in assessing 275
- cystocele repair 104
- cystoscopy
  - in pelvic organ prolapse repair 105
- cytokine modulation
  - for unexplained RPL 140
- cytomegalovirus (CMV)
  - in pregnancy 343–5, **344**, 344, **345**, 345
  - level of evidence 350
- danazol
  - in adenomyosis pain management 79
  - in endometriosis pain management 79
- DC placenta *see* dichorionic (DC) placenta
- D&E *see* dilatation and evacuation (D&E)
- deceleration(s)
  - defined **498**, 499–500, **499**, 501, 500
  - early **498**, 499–500, 500
  - in FHR
    - physiology of 502–3, 503
  - late **498**, **499**, 500, 500
  - prolonged **498**, **499**, 500
  - variable **498**, **499**, 500, 501
- deeply infiltrating endometriosis (DIE)
  - laparoscopic management of 80
  - prevalence of 76
- deep vein thrombosis (DVT)
  - case scenario 355
  - during pregnancy
    - diagnosis of 357
- delayed postpartum pre-eclampsia
  - defined 256–7
- delivery *see also* labor and delivery
  - cardiomyopathy in 280
  - forceps vs. vacuum 583–4, 585
  - operative vaginal 583–91 *see also* operative vaginal delivery (OVD)
  - spontaneous 569–81 *see also* spontaneous delivery
  - VBAC 419–30 *see also* vaginal birth after cesarean (VBAC) delivery
- depression
  - menopause and 157–8
  - postpartum 377
  - pregnancy-related 377–84
    - case scenario 377
    - clinical questions 377–81
    - prevalence of 377
    - psychiatric disease risk factors associated with 378
  - in women who wish to or have recently conceived
    - discontinuance of psychiatric medications by 377–8
- DES *see* diethylstilboestrol (DES)
- diabetes mellitus (DM) 297–302 *see also* gestational diabetes mellitus (GDM)
  - case scenario 297
  - clinical questions 297–302
  - gestational *see* gestational diabetes mellitus (GDM)
  - preconception counseling for women with 203–4
  - pregestational
    - preconception control of 203–4
  - in pregnancy
    - types of 297, **298**
    - White classification for 297, **298**
- diabetic nephropathy
  - in pregnancy 291
- dialysis
  - for CKD in pregnancy 292–3
- dichorionic (DC) placenta 467–8
- DIE *see* deeply infiltrating endometriosis (DIE)
- diet
  - in HG management 228
- diethylstilboestrol (DES) 2
- diffuse adenomyosis 76
- dilatation and evacuation (D&E)
  - induced abortion by 24–5
  - for mid-trimester induction of labor 538, **538**
- dilated cardiomyopathy 279



- dilator(s)
  - hygroscopic
  - in cervical ripening **531**, 532
- dimenhydrinate
  - in HG management **228**, 229
- dizygotic (DZ) conceptions 467–8
- DM *see* diabetes mellitus (DM)
- Doppler studies
  - in identifying growth-restricted fetuses at risk for adverse pregnancy outcomes 453–6, 454, 455, **456**
- doxylamine
  - in HG management 229
- droperidol
  - in HG management 230
- drug(s) *see also specific types and* medication(s)
- drug absorption
  - physiologic changes during pregnancy effects on 234, **235**
- drug disposition
  - physiologic changes during pregnancy effects on 234–6, **235**
- drug distribution
  - physiologic changes during pregnancy effects on 234, **235**
- drug elimination
  - physiologic changes during pregnancy effects on **235**, 236
- drug metabolism
  - physiologic changes during pregnancy effects on 234–6, **235**
- drug toxicities
  - fetal 238, **239**
- drug use
  - recreational
  - preconception care related to 207–8
- D-transposition of great arteries
  - in pregnancy 274
  - L-transposition of great arteries *vs.* 275
- duloxetine
  - for CPP 52, **53**
- duplex compression sonography
  - for VTE in pregnancy 561, **563**
- DVT *see* deep vein thrombosis (DVT)
- dysfunctional uterine bleeding 13
- dysplasia(s)
  - cervical 189–95 *see also* cervical intraepithelial neoplasia (CIN); CIN
- dystocia
  - shoulder
    - cesarean delivery in prevention of 460, **460**
- DZ conceptions *see* dizygotic (DZ) conceptions
- early deceleration
  - defined **498**, 499–500, 500
  - physiology of 502
- early miscarriage
  - recurrent
    - APS and 326
- “Early Obstetrical Warning System”
  - in management of VTE events in pregnant women admitted to hospital 562–5
- EBM *see* evidence-based medicine (EBM)
- echocardiography
  - fetal 489
- eclampsia
  - in mothers of multiple gestations 468, **469**
- ectopic pregnancy (EP) 33–47
  - ARTs and 33, 35
  - background 33
  - causes of 35–6
  - cervical
    - local therapy in 42
  - clinical questions 34–9
  - defined 33
  - described 35
  - diagnosis of 36–8
  - epidemiology of 34
  - heterotopic
    - local therapy in 42
  - historical perspective 34
  - incidence of 34
  - interstitial
    - local therapy in 41
  - management of 39–42
    - expectant 42
    - local therapy 41–2
    - medical 40–1
    - surgical 39–40
  - miscarriage *vs.* 39
  - morbidity and mortality effects of 34
  - ovarian
    - local therapy in 42
  - prevalence of 33
  - PUL 38
  - Rh status and antibody screen in women with 42
  - risk factors for 34–5
  - sites of 35
  - symptoms of 35–8
- ectopic pregnancy (EP) rupture 36
- ECV *see* external cephalic version (ECV)
- EFM *see* electronic fetal heart rate monitoring (EFM)
- EFW *see* estimated fetal weight (EFW)
- electronic fetal heart rate monitoring (EFM) *see also under* fetal heart rate (FHR)
  - adjunct methods of 508–9
  - background 495
  - criteria for hypoxic neurologic injury 504–5, 505, **505**
  - interpretation of 503–5, 504, **504**, 505, **505**
  - interruption of oxygen transfer from environment to fetus
    - during 503–4, 504, **504**
  - management with 505–8, 506, **507**
    - confirm FHR and uterine activity 505, 506
    - evaluate FHR components 505–6, **507**
    - expectant management *vs.* delivery 508
    - re-evaluate FHR tracing 506–8, 506, **507**
  - principles of 504, 505
  - randomized trials of
    - vs.* intermittent FHR auscultation 495
- embryonic anomalies
  - EP and 35–6
- embryonic demise
  - multiple pregnancies and births and 470
- emergency(ies)
  - obstetric 559–68 *see also specific types and* obstetric emergencies

- emergency(ies) (*continued*)
- emergency contraception 94
- endocrine disorders
- amenorrhea 109–13
- endometrial ablation/resection
- in HMB management 18, **18**
- endometrial cancer 181–8
- case scenario 181
- clinical questions 181–6
- minimally invasive surgery for 183–4
- premenopausal women with
- Lynch syndrome in 186
- ovarian removal in management of 184–5
- prognosis of 184–5
- prognosis of
- lymph node dissection in 181–3
- endometrioma
- fertility effects of 81–2
- endometriosis 75–87
- ASRM staging system for 75
- background 75–6
- case scenario 75
- clinical questions 76–83
- deeply infiltrating 76, 80
- evaluation for 77
- hysterectomy for
- ovarian preservation in women undergoing 83
- infertility due to
- management of 82
- management of
- peri-operative medical therapy in 82–3
- manifestations of 75–6
- pain symptoms of
- management of 78–80
- prevalence of 75
- search strategy 76
- severity of 75
- sites of 75
- types of 75–6
- environmental toxins
- preconception care related to 207–8
- EP *see* ectopic pregnancy (EP)
- EPCs program *see* US Evidence-based Practice Centers (EPCs) Program
- epilepsy
- case scenario 315
- clinical questions 316–17
- grading of evidence 317
- in pregnancy 315–17
- background 315–16
- fetal effects of 238–9, **239**
- prevalence of 315
- search strategy 317
- seizures in
- causes of 316
- ergometrine
- in AMTSL 577
- ESHRE *see* European Society of Human Reproduction and Embryology (ESHRE)
- ESHRE/ESGE classification system
- of fibroids 63
- Essure sterilization 93
- estimated fetal weight (EFW)
- case scenario 451
- cesarean delivery and
- in shoulder dystocia prevention 460, **460**
- in multiples 472
- estrogen
- for menopause 158
- EURAP *see* International Registry of Antiepileptic Drugs and Pregnancy (EURAP)
- European Society of Human Reproduction and Embryology (ESHRE)
- on diagnostic tests for RPL 132, 133
- evidence-based medicine (EBM)
- defined 2
- in OB/GYN 1–7
- Cochrane Collaboration 5, **5**
- critically appraising studies and assessing strength of literature 4–5, **5**
- EPCs Program in 5–6
- evidence-based resources 5, **5**
- formulating questions 3–4, **3**
- history 1–2
- literature search and identifying relevant studies 4
- steps in 3, **3**
- systematic review processes 2–3, **3**, 2
- USPSTF in 5–6
- for RPL 140–1
- evidence-based obstetrics
- steps in 3, **3**
- excisional procedures
- in CIN management 191
- external cephalic version (ECV)
- in effort to turn fetus into cephalic presentation 521
- for third trimester malpresentation 522–3
- failed abortion 26–7
- fallopian tubes
- EP within 35
- famciclovir
- for recurrent HSV infection 58, **58**
- FASTER trial 215–16, 490
- female pattern hair loss
- PCOS and 122, 122
- Ferriman-Gallwey (FG) scoring system 120–2, 120–2, **122**
- fertility
- endometrioma impact on 81–2
- fibroids effect on 65, **65**
- fertility desires
- counseling related to 90
- fetal anomalies 487–94
- background 487
- case scenario 487
- delivery mode and timing related to 489–90
- diagnosis of
- associated findings 488
- chromosome microarray analysis in 487–8

- imaging in 488–9
  - genetics of 487–8
  - introduction 487
  - management of
    - surgical 489
  - maternal risks associated with 490–1
  - prevalence of 487
  - risk factors for 490
  - termination due to 490
  - twinning and 488
  - types of 487
- fetal assessment
  - multiple pregnancies and births and 472–3, 473
- fetal death
  - APS and 326
- fetal demise
  - intrauterine 479–85 *see also* stillbirth(s)
  - mid-trimester induction of labor secondary to
    - induction of labor vs. D&E for 538, **538**
  - multiple pregnancies and births and 470
- fetal drug toxicities 238, **239**
- fetal fibronectin (FFN)
  - in identifying risk factors for preterm birth 387
- fetal growth
  - disorders of 451–65 *see also specific disorders*
    - background 451–2
    - case scenario 451, 460–1
    - clinical questions 452–60
  - multiple pregnancies and births impact on 472
- fetal growth restriction (FGR) 451–65 *see also* fetal growth, disorders of; growth-restricted fetuses
  - antepartum surveillance of
    - perinatal outcomes of 453
  - case scenario 451, 460–1
  - defined 451
  - detection of
    - customized fetal growth curves in 452–3
  - management of
    - vitamins and antioxidants in 457
  - in multiples 472
  - neonatal health consequences of 458, **459**
  - neurodevelopmental outcomes associated with 458, **459**
  - prevention of
    - vitamins and antioxidants in 457
- fetal heart rate (FHR) 499
- fetal heart rate (FHR) auscultation
  - EFM vs. 495, **496**
- fetal heart rate (FHR) definitions
  - acceleration **498**, 499, **499**
  - baseline 497, **498**, **499**
  - deceleration **498**, 499–500, **499**, 501, 500
  - NICHD on 497–501
  - sinusoidal pattern **498**, **499**, 500–1, 501
  - standardized
    - evolution of 495, 497
  - variability 497–9, **498**, **499**, 499
- fetal heart rate (FHR) patterns
  - physiology of 501–3, 503
  - accelerations 502
    - baseline 502
    - decelerations 502–3, 503
    - variability 502
- fetal karyotype
  - abnormal 133
- fetal macrosomia
  - prophylactic induction of labor for 458, 460
- fetal neuroprotection
  - magnesium sulfate in 400
- fetal presentations
  - types of 521
- fetal pulse oximetry
  - in intrapartum FHR monitoring 508
- fetal thyroid disease 310
- fetal warfarin syndrome 206
- fetal well-being
  - in post-term pregnancy
    - tests for 434–5
- fetus(es) *see also under* fetal
  - appendicitis in pregnancy risks to 372–3
  - breakthrough seizures impact on 316
  - cesarean delivery–related effects on 585, **586**
  - congenital heart disease in pregnant women effects on 275–6
  - drug toxicities affecting 238, **239**
  - echocardiography of 489
  - GDM effects on 298
  - Graves' disease in pregnancy effects on 308–10
  - growth-restricted *see* growth-restricted fetuses
  - HG effects on 226
  - induction of labor effects on 527–30, **528**
  - maternal asthma effects on 247–8, **248**
  - maternal pharmacotherapy effects on 238–9, **239**, **238**
  - MG effects on 321
  - multiple pregnancies and births impact on 469–73, **469**, 471, 473
  - OVD–related effects on 585, **586**
  - post-term pregnancy risk factors for 432, **433**
  - size of
    - impact on uterine rupture 421
  - valvular lesions during pregnancy effects on 271
- FFN *see* fetal fibronectin (FFN)
- FGR *see* fetal growth restriction (FGR)
- FHA *see* functional hypothalamic amenorrhea (FHA)
- FHR *see* fetal heart rate (FHR)
- fibroid(s) 63–74
  - causes of 64
  - classification of 63
  - diagnosis of 64, 65
  - epidemiology of 63
  - ESHRE/ESGE classification system of 63
  - evidence-based pregnancy outcomes related to 65–6, **65**, **66**
  - fertility effects of 65, **65**
  - HLRCC and 64
  - introduction 63
  - management of
    - effects of **70**
    - evidence-based 65, 67–9
    - LNG-IUDs 68
    - medical 67–8

- fibroid(s) (*continued*)
  - MRg-FUS in 68–9, **70**
  - surgical 67
  - pressure/pain from 65
  - prevalence of 63
  - quantitative measures of 66–7
  - uterine 63–74
  - vaginal bleeding related to 65
- fibronectin
  - fetal
    - in identifying risk factors for preterm birth 387
- FIGO *see* International Federation of Gynecology and Obstetrics (FIGO)
- First and Second Trimester Evaluation at Risk (FASTER) trial 215–16, 490
- first stage of labor
  - clinical questions 570–1, 570, **570**
  - Greenberg maternal age median length of **571**
- first trimester
  - combined screening
    - in pregnant women with low or average risk for aneuploidy 214–15, **214**
  - induced abortion during
    - methods of 23–4
  - vaginal bleeding in 33
- focal adenomyosis 76
- folic acid
  - in NTDs prevention 202–3
- fondaparinux
  - for VTE during pregnancy 359
- Fontan procedure 275
- forceps delivery
  - vacuum delivery vs. 583–4, 585
- “Friedman’s Curve” 569, 570
- functional hypothalamic amenorrhea (FHA) 111
  
- gabapentin
  - for CPP 52
- gastrointestinal disorders
  - in pregnancy 365–76 *see also specific disorders*
  - appendicitis 369–73
  - cholelithiasis 365–7
  - IBD 139
  - ICP 368
  - pancreatitis 367–8
- GDM *see* gestational diabetes mellitus (GDM)
- Gemeprost
  - in induced abortion 23
- general gynecology 11–97
- genetics
  - of fetal anomalies 487–8
- genital herpes simplex virus (HSV)
  - clinical presentations of 56
  - treatment of 58, **58**
- genital tract infections 55–62
  - background 55
  - case scenario 55
  - clinical presentations of 55–6
  - during pregnancy 59
  - clinical questions 55–60
  - HSV 56–8, **58**
  - search strategy 55
  - treatment of 57–60
    - in pregnancy 59–60
- genital warts
  - clinical presentations of 56
  - diagnosis of 57
  - treatment of 58–9
- genitourinary syndrome
  - menopause and 157
- gestational diabetes mellitus (GDM)
  - causes of 297
  - diagnostic criteria for 299–300, **299**
  - fetal effects of 298
  - labor and delivery for women with 300
    - maternal blood glucose monitoring and control during 300–1, **300**
    - monitoring in postpartum care 301
  - in mothers of multiple gestations 468, **469**
  - in pregnancy
    - types of 297, **298**
  - screening for 297–8
  - treatment of 299–300
- gestational hypertension 257
- gestational transient thyrotoxicosis
  - HG related to 226
- glomerulonephritis
  - acute
    - vs. pre-eclampsia **292**
- glucose intolerance
  - classification of 297, **298**
- GnRH agonists *see* gonadotropin releasing hormone (GnRH) agonists
- gonadotropin(s)
  - for unexplained subfertility 147
- gonadotropin releasing hormone (GnRH) agonists
  - in adenomyosis pain management 79
  - in endometriosis pain management 78
  - for fibroids 67, **70**
- gonorrhea
  - clinical presentations of 55
  - diagnosis of 56–7
  - treatment of 57
- GRADE Working Group 4, **4**
- Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group 4, **4**
- Graves’ disease
  - hyperthyroid disease due to
    - prevalence of 308
  - hypothyroid disease due to 303
  - in pregnancy 308–10
    - fetal risks associated with 308–10
    - incidence of 308
    - management of 308, 309
    - thyroid function and antibody tests for 309–10
- GRIT *see* Growth Restriction Intervention Trial (GRIT)
- growth-restricted fetuses
  - NSTs and BPPs in antepartum surveillance of

- perinatal outcomes of 453
- at risk for adverse pregnancy outcomes
  - Doppler studies in identifying 453–6, 454, 455, **456**
  - timing of delivery for 456–7
- Growth Restriction Intervention Trial (GRIT) 456–7
- gynecology 9–195
  - general 11–97
- hair loss
  - female pattern
    - PCOS and 122, 122
- Hashimoto's thyroiditis 303
- Hayman suture
  - in PPH management 549, 550
- HCM *see* hypertrophic cardiomyopathy (HCM)
- healthcare teams
  - in obstetric emergencies 566
- heart disease *see specific types and* cardiac disease
- heart valves
  - during pregnancy 270–1
- heavy menstrual bleeding (HMB) 13–20
  - acute anemia with 15
  - background 13–14, **13**
  - clinical questions 14–18
  - management of
    - antifibrinolytics in 15–16
    - COCs in 16, **17**
    - endometrial ablation/resection in 18, **18**
    - hysterectomy in 18, **18**
    - injected/depot progestogens in 18
    - LNG-IUS in 16–18, **17**
    - NSAIDs in 16, **17**
    - oral progestogens in 15, **17**
    - pharmacological 15–18, **17**
  - tests for 14–15
- Helicobacter pylori*
  - HG related to 225–6
- Hellin–Zellany rule
  - for twins, triplets, and quadruplets 467
- HELLP (hemolysis, elevated liver enzymes, and low platelet) syndrome 256
- hematologic disease 335–42 *see also specific types*
  - background 335
  - case scenario 335
  - clinical questions 335–40
- hemoglobin disorders
  - during pregnancy
    - identification and management of 336–7, **337**
- hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome 256
- hemorrhage *see also* bleeding
  - antepartum 407–17 *see also* antepartum hemorrhage (APH)
  - induced abortion and 26
  - postpartum 545–57 *see also* postpartum hemorrhage (PPH)
- heparin(s)
  - for hereditary thrombophilias 139, **140**
  - low-molecular weight *see* low-molecular weight heparin (LMWH)
  - during pregnancy 206
  - for unexplained RPL 139, 139
  - unfractionated
    - for VTE during pregnancy 358–9
- herbal preparations
  - in HG management 228
  - in post-term pregnancy management 436
- hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
  - fibroids due to 64
- hereditary thrombophilias
  - aspirin for 139
  - heparins for 139, **140**
  - as risk factor for RPL 134
- herpes simplex virus (HSV)
  - diagnosis of 57
  - genital
    - clinical presentations of 56
    - treatment of 58, **58**
  - PPROM management related to 402
- heterotopic ectopic pregnancy (EP)
  - local therapy in 42
- heterotopic pregnancy 33–4
  - ARTs and 33
- HG *see* hyperemesis gravidarum (HG)
- high-order multiple pregnancies
  - hypertensive disorders in 468, **469**
  - rare occurrence of 467
- hirsutism
  - PCOS and 119–22, 120, **122**
- HIV
  - PPROM management related to 402
- HLRCC *see* hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
- HMB *see* heavy menstrual bleeding (HMB)
- hormone replacement therapy (HRT)
  - case scenario 155
  - for menopause 158–9
- hormone supplementation
  - for RPL 137
  - for unexplained RPL 137
- HPV *see* human papillomavirus (HPV)
- HRT *see* hormone replacement therapy (HRT)
- HSV *see* herpes simplex virus (HSV)
- human immunodeficiency virus (HIV)
  - PPROM management related to 402
- human papillomavirus (HPV)
  - cervical cancer related to 165, 167
  - CIN and 165, 167, 189–95
  - prevalence of 190–1
  - clinical questions 189–92
  - detection of
    - diagnostic tests vs. cervical cytology in 167–8
  - vulvovaginal cancers related to 174–5
- human papillomavirus (HPV) vaccines
  - in CIN prevention 191–2
- hydration
  - in preterm labor management 392
- hydrops fetalis 513–19 *see also* congenital pulmonary airway malformation (CPAM)
  - aggravation of

- hydrops fetalis (*continued*)
  - case scenario 513, 514
  - background 513–14
  - case scenario 513–14, 514, 515
  - classification of 513
  - clinical questions 514–18
  - CPAM and 513–19
  - defined 513
  - findings associated with
    - case scenario 513, 514
  - non-immune
    - case scenario 513, **516**
    - causes of 515, **516**
    - diagnosis of 515, 517, 517
    - incidence of 515
    - prevalence of 513
    - survival rates 517, **518**
    - vs. immune 513
- hydroxychloroquine
  - for SLE 137
- hygroscopic dilators
  - in cervical ripening **531**, 532
- hyperandrogenemia 118
- hyperandrogenism 118
- hyperemesis gravidarum (HG) 225–32
  - case scenario 225
  - causes of 225–6
  - defined 225
  - described 225
  - differential diagnosis 226–7, **227**, **228**
  - effects of 226
  - hyperthyroidism and 310–11
  - incidence of 225
  - laboratory abnormalities in **227**
  - laboratory evaluation for 227
  - management of 227–30, **228**
    - ACOG on 229
    - acupuncture in 228
    - diet in 228
    - herbal options in 228
    - hypnosis in 228
    - non-pharmacologic 228
    - pharmacologic **228**, 229–30
    - recommendations 230
  - risk factors for 225
- hypergonadotropic primary amenorrhea 110–11
- hypergonadotropic secondary amenorrhea 111
- hyperprolactinemia
  - treatment of 113
- hypertension
  - chronic 258
    - preconception care for women with 204–5
  - gestational 257
  - pre-existing 258
    - superimposed pre-eclampsia on 258–9
  - pregnancy-induced 257
- hypertensive disorders of pregnancy 255–64
  - background 255–9, **256**, **259**
  - case scenario 255, 259–62, **259**
    - categories of 255
    - clinical questions 259–62, **259**
    - in high-order multiple pregnancies 468, **469**
    - inpatient vs. outpatient evaluation for 259–60
    - pre-eclampsia with 257
    - risk factors for
      - case scenario 259, **259**
- hyperthyroid disease 308–11
  - background 308
  - case scenario 308
  - causes of 308
  - prevalence of 308
- hyperthyroidism
  - HG and 310–11
  - prevalence of 303
- hypertrophic cardiomyopathy (HCM) 278
- hypnosis
  - in HG management 228
- hypothalamic amenorrhea 111
  - functional 111
- hypothalamus
  - menopause effects on 156
- hypothyroid disease
  - defined 303
  - poor perinatal and childhood outcomes related to 305–6
    - in pregnancy
      - clinical questions 304–8
      - T4 dose in 304
      - thyroid function and antibody tests for 304–5
- hypothyroidism
  - maternal subclinical 306–7
  - poor perinatal and childhood outcomes related to 305–6
    - in pregnancy
      - routine screening for 307
  - subclinical *see* subclinical hypothyroidism
  - treatment of 113
- hypothyroxinemia
  - poor perinatal and childhood outcomes related to 305–6
- hypoxic neurologic injury
  - criteria for 504–5, 505, **505**
- hysterectomy
  - in adenomyosis pain management 81
  - for endometriosis
    - ovarian preservation in women undergoing 83
  - for fibroids 67, 69
  - in HMB management 18, **18**
  - number of
    - impact on uterine rupture 421
  - in placenta accreta management 553
    - alternatives to 553–4
  - in uterine prolapse management 102
- hysteropexy
  - in uterine prolapse management 102
- IBD *see* inflammatory bowel disease (IBD)
- ICP *see* intrahepatic cholestasis of pregnancy (ICP)
- idiopathic polyhydramnios
  - antenatal testing for diagnosis of fetal well-being related to 445
- IHI *see* Institute for Healthcare Improvement (IHI)

- immunosuppression
  - vulvovaginal cancers related to 174–5, **174**
- immunotherapy
  - for unexplained RPL 139–40
- incontinence
  - urinary 101–6
- indomethacin
  - in polyhydramnios management 446–7, **446**
- induced abortion 21–32
  - background 21
  - case scenario 21
  - clinical questions 21–8
  - contraceptive methods initiated after 27–8
  - counseling prior to 22
  - failed 26–7
  - follow-up after 28
  - medical assessments prior to 22
  - medical “induction” 24
  - methods of
    - in first trimester 23–4
    - in second trimester 24–5
  - prevalence of 21
  - risks associated with 25–7
  - safety of 21
  - subsequent reproduction outcomes related to 27
- induction of labor 527–34
  - background 527
  - benefits of 527
  - case scenario 527
  - cervical ripening in 531–3, **531** *see also specific methods, e.g.,*
    - membrane sweeping
  - clinical questions 527–34
  - criteria for 527
  - described 527
  - failed outcome 534
  - fetal and maternal outcomes related to 527–30, **528**
  - impact on uterine rupture 422, 423–6
  - indications for 527–8, **528**
  - mid-trimester 537–8, **538** *see also mid-trimester induction of labor*
  - labor
  - oxytocin in **531**, 533–4
    - cesarean delivery and 533–4
  - prevalence of 527
  - preventive 528
  - prophylactic
    - for fetal macrosomia 458, 460
  - prostaglandins in **531**, 532–3
  - risk-based 528
  - risk factors for 527–8
  - risk of cesarean delivery with 528–9
  - success of
    - tests in determination of 530–1, **530**
  - types of 528
- infant(s)
  - LBW
    - multiple pregnancies and births and 472
  - VLBW
    - multiple pregnancies and births and 472
- infection(s) *see also specific types*
- genital tract 55–62 *see also specific types and* genital tract infections
  - induced abortion and 26
- in pregnancy 343–54 *see also specific types*
  - CMV 343–5
  - level of evidence 350
  - listeriosis 348–50
  - parvovirus 345–6
  - VZV 346–8, **347**
- as risk factor for RPL 135
- infertility
  - adenomyosis and 76
  - atypical APS laboratory test results 326
  - endometriosis-related
    - management of 82
  - ovulatory
    - PCOS and 124–5, **126**
  - PCOS and
    - management of 125, **126**
  - unexplained 145–53 *see also* unexplained subfertility
- inflammatory bowel disease (IBD)
  - in pregnancy 139
- informed consent
  - for OVD 585
- inguinofemoral lymph node dissection
  - SLND vs.
    - in early-stage vulvar cancer detection 175–7, **176**
- inhaled beta-agonists
  - impact on pregnancy women with asthma **250**, 251
- inhaled corticosteroids
  - impact on pregnant women with asthma 249–51, **250**
- injected/depot progestogens
  - for HMB 18
- Institute for Healthcare Improvement (IHI)
  - on “bundle” 563
- interdelivery interval
  - impact on uterine rupture 421–2
- intermittent FHR auscultation
  - EFM vs. 495, **496**
  - randomized trials of EFM vs. 495
- International Federation of Gynecology and Obstetrics (FIGO)
  - on AUB 13
- International Registry of Antiepileptic Drugs and Pregnancy (EURAP)
  - on seizures in pregnancy 315–16
- interoception care
  - aim of 201
  - rationale for 202
- interoception period
  - defined 201
- interstitial ectopic pregnancy (EP)
  - local therapy in 41
- interval laparoscopic ligation 93
- intrahepatic cholestasis of pregnancy (ICP) 368, 479
  - case scenario 482
  - causes of 482
  - defined 482
  - management of
    - RCOG on 483



- intrahepatic cholestasis of pregnancy (ICP) (*continued*)  
 prevalence of 482  
 stillbirth and 483
- intrapartum factors  
 impact on uterine rupture 422
- intrapartum FHR monitoring  
 fetal pulse oximetry in 508  
 ST segment analysis in 508
- intrauterine devices (IUDs)  
 after induced abortion 27  
 levonorgestrel releasing  
 for fibroids 68  
 progesterone-containing  
 for HMB 16–18, **17**
- intrauterine fetal demise 479–85 *see also* stillbirth(s)
- intra-uterine insemination  
 for unexplained subfertility 148–9
- intravenous immunoglobulin (IVIg)  
 for patients with RPL and APS 136
- in vitro fertilization (IVF) 34  
 for unexplained subfertility 149
- iron  
 preparations of 336, **336**
- irritable bowel syndrome  
 diagnosis of **53**
- ischemic stroke  
 during pregnancy 317–19 *see also* stroke, during pregnancy
- isotretinoin  
 for acne 207  
 during pregnancy 207
- IUDs *see* intrauterine devices (IUDs)
- IVF *see* in vitro fertilization (IVF)
- IVIg *see* intravenous immunoglobulin (IVIg)
- karyotype  
 abnormal fetal 133
- karyotyping  
 parental 133
- kidney(ies) *see under* chronic kidney disease (CKD); renal
- kidney disease  
 chronic *see* chronic kidney disease (CKD)
- labor *see also* labor and delivery  
 active  
 centimeter progression during 570  
 initiation of 570  
 arrest of 535  
 augmentation of 527–37 *see also* augmentation of labor  
 course of  
 conduction anesthesia impact on 537  
 defined 570  
 duration of  
 maternal age in **571**  
 first stage of *see* first stage of labor  
 functional divisions of 534  
 induction of 527–34 *see also* induction of labor  
 normal progression of 569  
 passive 571  
 preterm 385–95 *see also* preterm labor
- progression of  
 maternal age as factor in 570–1  
 obesity effects on 571  
 prolonged stage of  
 maternal or neonatal morbidity related to 536–7
- prophylactic induction of  
 for fetal macrosomia 458, 460
- protracted active phase of  
 oxytocin in 535–6
- protracted latent phase of  
 management of 535
- pushing during 572, **573**, 572, **575**
- second stage of *see* second stage of labor
- third stage of *see* third stage of labor
- trial of 419
- labor and delivery  
 GDM and 300  
 for growth-restricted fetuses 456–7
- placental abruption and  
 timing of 412
- preterm  
 in mothers of multiple gestations 469
- spontaneous delivery  
 methods for 569–81 *see also* spontaneous delivery
- timing of  
 PPROM management and 401
- valvular lesions during pregnancy impact on 271
- for women with congenital cardiac lesions  
 preferred methods 276
- lactation  
 antipsychotic use during 380–1  
 benzodiazepine use during 381  
 lithium use during 381  
 valproate use during 381
- laparoscopic cholecystectomy  
 for cholelithiasis in pregnancy 366–7
- laparoscopic ovarian drilling  
 in PCOS management 125
- laparoscopic surgery  
 in adenomyosis pain management 80  
 in EP management 39
- laparoscopy  
 in adenomyosis pain management 80  
 in endometriosis evaluation 77  
 for fibroids 69  
 in identifying CPP causes in women 51–2  
 robotic-assisted  
 for fibroids 69  
 for unexplained subfertility 149–50
- laparotomy  
 in endometriosis evaluation 77  
 in EP management 39  
 for fibroids 69
- LARC methods *see* long-acting reversible contraception (LARC)  
 methods
- large for gestational age (LGA)  
 defined 451–2
- large loop excision of transformation zone (LLETZ)  
 in CIN management 191

- laser ablation
  - in CIN management 191
- laser conization
  - in CIN management 191
- late deceleration
  - defined **498, 499**, 500, 500
  - physiology of 502–3, 503
- latency period
  - PPROM management in 399
- latent labor
  - protracted
    - management of 535
- LBW *see* low-birthweight (LBW)
- LEEP *see* loop electrosurgical excision procedure (LEEP)
- leiomyomas
  - uterine *see* fibroid(s)
- letrozole
  - for fibroids 67–8, **70**
- leuprolide
  - for fibroids 67
- levonorgestrel releasing intrauterine devices (LNG-IUDs)
  - in adenomyosis pain management 79
  - for fibroids 68
- LGA *see* large for gestational age (LGA)
- lifestyle modifications
  - in PCOS-related infertility management 125, **126**
- listeriosis
  - in pregnancy 348–50
- lithium
  - during lactation 381
  - during pregnancy 206
- LLETZ *see* large loop excision of transformation zone (LLETZ)
- LMWH *see* low-molecular weight heparin (LMWH)
- LNG-IUDs *see* levonorgestrel releasing intrauterine devices (LNG-IUDs)
- LNG-IUS
  - for HMB 16–18, **17**
- long-acting reversible contraception (LARC) methods 89
  - candidates for 92
  - in women with history of STIs 92
- loop electrosurgical excision procedure (LEEP)
  - in CIN management 191
- low-birthweight (LBW) infants
  - asthma during pregnancy and 248, **248**
  - multiple pregnancies and births and 472
- low-dose aspirin
  - in FGR management and prevention 457
- low-lying placenta
  - diagnosis of 408
  - vasa previa related to 414
- low-lying placenta previa
  - diagnosis of 408
- low-molecular weight heparin (LMWH)
  - in thromboprophylaxis in obese women 596–7
  - for VTE during pregnancy 359
- L-transposition of great arteries
  - D-transposition of great arteries *vs.* 275
  - Lying-in Hospitals 1
  - lymph node dissection
    - in endometrial cancer prognosis 181–3
- Lynch syndrome
  - in premenopausal women with endometrial cancer 186
- macrosomia 452
  - fetal
    - prophylactic induction of labor for 458, 460
    - maternal adverse events associated with 452
- magnesium sulfate
  - in PPRM management 400
  - in reducing neonatal morbidity and mortality from preterm birth 390–1
- magnetic resonance-guided high-intensity focused ultrasound (MRg-FUS or MR-HIFU)
  - for fibroids 68–9, **70**
- magnetic resonance imaging (MRI)
  - for appendicitis in pregnancy 371–2, **371**
  - in fetal anomalies diagnostic testing 488–9
  - in low-lying placenta diagnosis 408
  - T1- and T2-weighted
    - in endometriosis evaluation 77
- major depressive disorder (MDD)
  - risk factors for 378
  - symptoms of 378
- major depressive episode
  - in pregnant women
    - adverse perinatal outcomes effects of 378–9
    - non-pharmacological treatments for 379–80
- malformation(s)
  - fetal-neonatal
    - multiple pregnancies and births and 469–70
- malformation syndromes
  - stillbirth related to 490
- malpresentation 521–4
  - background 521
  - defined 521
  - ECV in 521
  - late third trimester
    - risk factors for breech presentation related to 521
  - third trimester
    - breech vaginal delivery *vs.* cesarean delivery for 521–2
    - ECV for 522–3
- Marfan syndrome 273, 275, 276
- massage
  - uterine
    - in third stage of labor **576**, 577
- maternal age
  - in labor duration **571**
  - in labor progress 570–1
  - in length of second stage of labor 576
  - in multiple pregnancies and births 468
  - in uterine rupture 420–1
- maternal complications 245–439 *see also specific types, e.g.,* asthma
  - AF volume disorders 443–9
  - antepartum/intrapartum fetal surveillance 495–511
  - APH 407–17
  - APS 325–33
  - asthma 247–53
  - CVD 265–86

- maternal complications (*continued*)
  - depression 377–84
  - DM 297–302
  - fetal anomalies 487–94
  - fetal growth disorders 451–65
  - FHR monitoring 495–511
  - gastrointestinal disorders 365–76
  - GDM 297–302
  - hematologic disease 335–42
  - hydrops fetalis 513–19
  - hypertensive disorders of pregnancy 255–64
  - infections 343–54
  - intrauterine fetal demise 479–85
  - malpresentation 521–4
  - multiple pregnancies and births 467–77
  - neurologic disease 315–24
  - post-term pregnancy 431–9
  - PPROM 397–406
  - psychiatric disease 377–84
  - renal disease 287–96
  - stillbirths 479–85
  - thyroid disease 303–14
  - VBAC delivery 419–30
  - VTE 355–63
- Maternal-Fetal Medicine Unit Cesarean Registry 593
- maternal position
  - in second stage of labor 572–3, **573**
- maternal serum alpha-fetoprotein (MSAFP) screening
  - in NTDs detection 219
- maternal subclinical hypothyroidism *see* subclinical hypothyroidism
- McCall culdoplasty
  - in pelvic organ prolapse management 103
- MCDA placenta *see* monochorionic–diamniotic (MCDA) placenta
- MCMA placenta *see* monochorionic–monoamniotic (MCMA) placenta
- MDD *see* major depressive disorder (MDD)
- medical "induction" abortion 24
- Medical Outcomes Study Short-Form 36 (SF-36) Health Survey 67
- medicated IUDs that release levonogestrel (LNG-IUS)
  - for HMB 16–18, **17**
- medication(s)
  - with known teratogenic potential 206–7, **206**
- in pregnancy 233–43
  - for asthma 249, **250**
  - background 233
  - case scenario 233
  - clinical questions 233–9
  - fetal drug toxicities 238, **239**
  - fetal risks associated with 238–9, **239, 238**
  - pharmacokinetic changes related to 234–6, **235**
  - placenta effects on 236–8, 237
- medrol
  - dosing schedule for **228**
- membrane sweeping
  - in cervical ripening 531–2, **531**
- memory
  - menopause effects on 158
- menopause 155–61
  - amenorrhea related to 112–13
  - bodily effects of 158
  - case scenario 155
  - clinical questions 156–9
  - cognitive effects of 158
  - defined 155
  - depression in 157–8
  - endocrinological changes associated with 156
  - genitourinary syndrome and 157
  - hypothalamic changes with 156
  - memory effects of 158
  - mood disorders in 157–8
  - ovarian aging with 156
  - overview 155
  - search strategy 155–6
  - sleep disturbances in 157
  - symptoms of 157
  - treatment of 158–9
    - hormonal 158–9
    - HRT in 158–9
    - indications for 158
    - non-hormonal 159
  - uterine bleeding and 157
  - vasomotor symptoms in 157
- menorrhagia 13
- menstrual bleeding
  - abnormal 13–20 *see also* abnormal menstrual bleeding
  - heavy 13–20 *see also* heavy menstrual bleeding (HMB)
  - normal 13, **13**
- menstrual physiology
  - in amenorrhea evaluation 110
- metformin
  - in PCOS management 125
- methimazole
  - for Graves' disease in pregnancy 309, **310**
- methotrexate (MTX)
  - contraindications to 40
  - criteria for use 40
  - in EP management 40–2
- metoclopramide
  - in HG management 229
- MG *see* myasthenia gravis (MG)
- microangiopathic disorders
  - during pregnancy 340, **340**
- mid-trimester induction of labor 537–8, **538**
  - background 537
  - case scenario 537
  - clinical questions 538
  - secondary to lethal anomaly or fetal demise
    - induction of labor vs. D&E for 538, **538**
  - termination methods 538, **538**
- mifepristone
  - for fibroids 68, **70**
  - in induced abortion 23–4
- miscarriage 33–47 *see also* recurrent pregnancy loss (RPL)
  - atypical APS laboratory test results 326
  - background 33
  - case scenario 33

- causes of 133
- defined 131
- EP vs. 39
- incidence of 33
- prevalence of 131
- recurrent early
  - APS and 326
- misoprostol
  - in AMTSL 577, **577**
  - in induced abortion 23–4
  - in PPH management 546–7, **547**
- monochorionic–diamniotic (MCDA) placenta 467
- monochorionic–monoamniotic (MCMA) placenta 467
- monozygotic (MZ) conceptions 467–8
- mood disorders
  - menopause and 157–8
- morbid obesity
  - case scenario 593
  - cesarean delivery in women with 593
- mosaicism
  - amenorrhea related to 111
- mother(s)
  - age of *see* maternal age
  - appendicitis in pregnancy risks to 372–3
  - cesarean delivery–related effects on 585, **586**
  - fetal anomalies impact on 490–1
  - HG effects on 226
  - induction of labor effects on 527–30, **528**
  - length of second stage of labor impact on 574–5
  - multiple pregnancies and births impact on 468–9, **469**
  - OVD–related effects on 585, **586**
  - post-term pregnancy risk factors for 432, **433**
  - prolonged stage of labor effects on 536–7
- MRg-FUS *see* magnetic resonance–guided high-intensity focused ultrasound (MRg-FUS or MR-HIFU)
- MR-HIFU *see* magnetic resonance–guided high-intensity focused ultrasound (MRg-FUS or MR-HIFU)
- MS *see* multiple sclerosis (MS)
- MSAFP screening *see* maternal serum alpha-fetoprotein (MSAFP) screening
- MTX *see* methotrexate (MTX)
- multiple pregnancies and births 467–77
  - age as factor in 468
  - birthweight discordance in 472
  - delivery considerations 473–4
    - mode of delivery 474
    - timing of delivery 473–4
  - eclampsia and 468, **469**
  - EFW in 472
  - fetal assessment in 472–3, 473
  - fetal–neonatal consequences of 469–73, **469**, 471, 473
    - embryonic and fetal demise 470
    - fetal growth 472
    - malformations 469–70
    - TTTS 470–2, 471
  - GDM and 468, **469**
  - growth restriction in 472
  - hypertensive disorders and 468, **469**
  - maternal consequences of 468–9, **469**
  - outcome 474–5
  - pre-eclampsia and 468, **469**
  - preterm labor and delivery and 469
  - prevention vs. cure 475
- multiple sclerosis (MS)
  - causes of 319
  - during pregnancy 319–20
    - background 319
    - case scenario 319
    - clinical questions 319–20
    - grading of evidence 320
    - management of 320
    - search strategy 320
  - prevalence of 315, 319
- multiple sexual partners
  - EP related to 35
- multivitamins
  - in HG management 229
- musculo-skeletal abnormalities
  - in women of reproductive age with CPP 51
- myasthenia gravis (MG)
  - during pregnancy 320–2
    - background 321
    - case scenario 320–1
    - clinical questions 321
    - delivery and fetal well-being related to 321
    - grading of evidence 322
    - search strategy 321–2
    - thymectomy in preventing complications 321
- myomectomy
  - for fibroids 67, **70**
- MZ conceptions *see* monozygotic (MZ) conceptions
- NAAT *see* nucleic acid amplification testing (NAAT)
- National Institute of Child Health and Human Development (NICHD)
  - on FHR definitions 497–501 *see also specific terms and* NICHD definitions
- National Institute of Child Health and Human Development (NICHD) consensus report (2008) 497, **499**
- National Partnership for Maternal Safety (NPMS)
  - on VTE prevention during pregnancy 360, **361**
- natural killer (NK) cells
  - as risk factor for RPL 135
- neonate(s)
  - congenital heart disease in pregnant women risks to 275–6
  - health consequences of FGR on 458, **459**
  - length of second stage of labor impact on 575–6
  - morbidity and mortality related to
    - preterm labor– and birth–related 388, 390
  - multiple pregnancies and births impact on 469–73, **469**, 471, 473
  - prolonged stage of labor effects on 536–7
  - valvular lesions during pregnancy effects on 271
- neural tube defects (NTDs)
  - case scenario 201
  - in pregnant women
    - amniocentesis in detection of 220
    - MSAFP in detection of 219

- neural tube defects (NTDs) (*continued*)
  - ultrasound in 219–20
  - prevention of
    - folic acid in 202–3
- neurologic disease 315–24 *see also specific types*
  - epilepsy 315–17
  - introduction 315
  - MG 320–2
  - MS 319–20
  - in pregnancy 315–24
  - prevalence of 315
  - stroke 317–19
- neuroprotection
  - fetal
    - magnesium sulfate in 400
- NICHD *see* National Institute of Child Health and Human Development (NICHD)
- NICHD definitions
  - FHR-related 497–501 *see also specific terms and fetal heart rate (FHR) definitions*
  - general considerations 497
- NK cells *see* natural killer (NK) cells
- nodule(s)
  - thyroid
    - in pregnancy 311
- nonsteroidal anti-inflammatory drugs (NSAIDs)
  - for HMB 16, 17
- non-stress tests (NSTs)
  - in antepartum surveillance of growth-restricted fetuses
    - perinatal outcomes of 453
- no-scalpel vasectomy (NSV) 93–4
- NPMS *see* National Partnership for Maternal Safety (NPMS)
- NSAIDs *see* nonsteroidal anti-inflammatory drugs (NSAIDs)
- NSTs *see* non-stress tests (NSTs)
- NSV *see* no-scalpel vasectomy (NSV)
- NTDs *see* neural tube defects (NTDs)
- nucleic acid amplification testing (NAAT)
  - in genital tract infections 56–7
- obese women
  - cesarean delivery in 593–9 *see also* cesarean delivery, in obese women
  - postpartum thromboembolism in 596–7
- obesity
  - classification of 593
  - defined 205
  - impact on length of second stage of labor 576
  - labor progression impacted by 571
  - morbid 593
  - preconception care in management and prevention of 205–6
  - prevalence of 593
- OB/GYN *see* obstetrics/gynecology (OB/GYN)
- obstetric emergencies 559–68
  - background 559
  - cardiopulmonary arrest 565–6
  - healthcare teams performance during 566
  - introduction 559
  - PE 559–65
  - team-oriented care for 559–68
- VTE 560
- obstetrics/gynecology (OB/GYN)
  - EBM in 1–7 *see also* evidence-based medicine (EBM), in OB/GYN
  - OHSS *see* ovarian hyperstimulation syndrome (OHSS)
  - oligohydramnios 488
  - ondansetron
    - in HG management 228, 229–30
  - oocyte anomalies
    - EP and 35–6
  - open cholecystectomy
    - for cholelithiasis in pregnancy 366–7
  - operative delivery
    - vaginal delivery vs.
      - factors in second stage of labor determining 573–4, 573, 575
  - operative vaginal delivery (OVD) 583–91
    - case scenario 583
    - clinical options 583
    - decreasing trend in 583, 584, 585
    - evidence-based procedural aspects of 586
    - failed 587–8
    - forceps vs. vacuum 583–4, 585
    - future directions in 589
    - guideline considerations for 586
    - informed consent for 585
    - introduction 583–5, 584, 585
    - limitation of pulls and pop-offs in 587–8
    - maternal–fetal complications of 585, 586
    - pre-procedure checklist and clinical documentation for 585, 587, 588
    - prevalence of 583–5, 584, 585
    - quality metrics in 590
    - safety considerations 587–9
    - sequential instruments in 588–9
    - training, competency, and simulation in 589
    - ultrasound-assisted 589–90
  - OPK *see* over-the-counter ovulation predictor kit (OPK)
  - OPTIMAL trial 103
  - OPTIMUM trial 388
  - outflow tract abnormalities
    - amenorrhea related to 110
  - ovarian aging
    - menopause and 156
  - ovarian ectopic pregnancy (EP)
    - local therapy in 42
  - ovarian hyperstimulation syndrome (OHSS) 147
  - ovarian preservation
    - in women undergoing hysterectomy for endometriosis 83
  - ovarian removal
    - in endometrial cancer management in premenopausal women 184–5
  - ovarian stimulation
    - for unexplained subfertility 146–8
  - OVD *see* operative vaginal delivery (OVD)
  - over-the-counter ovulation predictor kit (OPK)
    - in PCOS management 125
  - overweight
    - defined 205
    - preconception care in management and prevention of 205–6

- ovulatory infertility
  - PCOS and 124–5, **126**
- Oxford Center for Evidence-based Medicine 4
- oxygen saturation
  - in assessing obstetric and fetal risks in women with cyanotic heart disease 275
- oxygen therapy
  - in FGR management and prevention 457
- oxytocin
  - in AMTSL 576–9, **576**, 578
  - effectiveness of 579
  - optimum dosage of 578, 578
  - optimum timing of 577
  - vs. other medications 577
  - route of 578
  - in cervical ripening **531**, 533–4
  - in induction of labor **531**, 533–4
  - in PPH management 547, **547**
  - in protracted active phase of labor 535–6
- pain
  - pelvic *see* chronic pelvic pain (CPP); pelvic pain
- pancreatitis
  - in pregnancy 367–8
- paracetamol
  - for CPP 52
- parental karyotyping
  - as risk factor for RPL 133
- parvovirus
  - in pregnancy 345–6
  - level of evidence 350
- passive labor 571
- PBAC *see* pictorial blood loss assessment chart (PBAC)
- PCOS *see* polycystic ovarian syndrome (PCOS)
- PE *see* pulmonary embolism (PE)
- pelvic floor prolapse 101–6 *see also* pelvic organ prolapse
  - background 101
  - case scenario 101
- pelvic organ prolapse 101–6
  - background 101
  - causes of 101
  - described 101–2
  - management of
    - cystoscopy during 105
    - pessaries in 102
    - surgical 102–3
    - types of 102–4
  - prevalence of 101
  - risk factors for 101
  - without SUI
    - management of 104–5
- pelvic pain 49–54
  - background 49–50
  - case scenario 49
  - chronic 49–54 *see also* chronic pelvic pain (CPP)
- PERC *see* Pulmonary Embolism Rule-out Criteria (PERC)
- percutaneous balloon mitral commissurotomy
  - for valvular lesions during pregnancy 270
- perimenopause
  - defined 155
  - endocrinological changes associated with 156
- perinatal mortality
  - asthma during pregnancy and 248, **248**
- peripartum cardiomyopathy (PPCM)
  - case scenario 277
  - clinical questions 277–80
  - defined 277–8
  - diagnosis of 278
  - management of 279–80
  - presenting features of 278
  - risk factors for 277–8
  - traditional forms of cardiomyopathy vs. 278–9
- peripartum complications 525–99
  - augmentation of labor 534–7
  - cesarean delivery in obese women 593–9
  - induction of labor 527–34
  - mid-trimester induction of labor 537–8, **538**
  - obstetric emergencies 559–68
  - OVD 583–91
  - PPH 545–57
  - spontaneous delivery 569–81
- pessaries
  - in pelvic organ prolapse management 102
- PGM *see* prothrombin G20210A (PGM)
- PGS *see* pregestational genetic screening (PGS)
- phenothiazines
  - in HG management 229
- PICOTS 3, **3**
- pictorial blood loss assessment chart (PBAC) 66–7
- pituitary disorders
  - amenorrhea related to 111–12
- placenta
  - DC 467–8
  - drug therapy during pregnancy effects of 236–8, 237
  - low-lying
    - diagnosis of 408
    - vasa previa related to 414
  - MCD 467
  - MCMA 467
  - morbidly adherent
    - methods in controlling/preventing hemorrhage 553–4
    - “rising” 408
- placenta accreta 551–4
  - case scenario 551
  - clinical questions 552–4
  - incidence of 551
  - management of
    - hysterectomy at time of delivery in 553
  - risk factors for 551
- placental abruption 411–13
  - case scenario 411
  - clinical questions 411–13
  - delivery timing with 412
  - expectant management for 413
  - prediction of 411
  - prevalence of 412
- placental arrangement
  - zygosity vs. 467

- placental arrangement (*continued*)
- placental insufficiency
  - preterm deliver for
    - APS and 326–7
- placenta percreta
  - management of 553
- placenta previa 407–11
  - bleeding
    - tocolysis in management of 409
  - case scenario 407
  - clinical questions 407–11
  - described 407–8
  - diagnosis of
    - TVS in 408
  - gestational stage for delivery planning and delivery 410
  - low-lying
    - diagnosis of 408
  - major
    - home management in care of 409–10
  - prevalence of 407–8
  - “rising placenta” 408
  - vaginal birth in pregnancies complicated by 410
- placenta previa accreta
  - management of 410–11
- placenta previa increta
  - management of 410–11
- placenta previa percreta
  - management of 410–11
- placentation
  - abnormal
    - tests for 552–3
- polycystic ovarian syndrome (PCOS) 117–29
  - acne and 122, 122
  - amenorrhea related to 112
  - AN and 122–3, 122
  - case scenario 117, 127–8
  - causes of 118, 119
  - clinical presentation of 119
  - clinical questions 117–27
  - defined 118, **118**
  - diagnosis of 119–23, 120–2, **122**
  - diagnostic criteria for 118, **118**, **123**
  - diagnostic tests for 123, **124**, 123
  - differential diagnosis **123**
  - epidemiology of 118–19
  - EP related to 34–5
  - hirsutism and 119–22, 120, **122**
  - infertility related to
    - management of 125, **126**
  - introduction 118
  - long-term health risks associated with
    - counseling on 125–6, **126**
  - management of 123–5
    - anti-androgens in 124
    - COCs in 123–4
    - laparoscopic ovarian drilling in 125
    - lifestyle modifications in 125, **126**
    - metformin in 125
    - OPK in 125
  - progestin-only approach in 124
  - SERMs in 125
  - weight reduction in 125
  - ovulatory infertility related to 124–5, **126**
  - pregnancy complications related to 125
  - prevalence of 118–19
  - as risk factor for RPL 134
- polyhydramnios
  - defined 443
  - described 443
  - diagnosis of
    - ultrasound in 444, **444**
  - fetal anomalies detection in pregnant patients with
    - ultrasound in 444–5, **445**
  - idiopathic
    - antenatal testing for diagnosis of fetal well-being related to 445
  - management of
    - AR in 445–6
    - indomethacin in 446–7, **446**
  - perinatal outcome related to
    - ultrasound in detection of 444, **444**
- polyzygotic conceptions 467–8
- postpartum care
  - monitoring of women with GDM 301
- postpartum counseling
  - on long-term maternal risk of CVD 261–2
- postpartum depression
  - case scenario 377
- postpartum hemorrhage (PPH) 545–57
  - background 545, **545**
  - case scenario 545
  - causes of 545, **545**
  - clinical questions 546–51
  - general search strategy 546
  - introduction 545
  - management of 546–8, **547**
    - arterial ligation in 549
    - bimanual uterine compression in 548–9
    - compression sutures in 549–50, 550
    - invasive procedures in 548–51, 550
    - stepwise approach to 546
    - systemic devascularization in 549
    - UAE in 550–1
    - uterine tamponade in 548–9
    - uterotonics in 546–7, **547**
- placenta accreta and 551–4 *see also* placenta accreta
- quantification of 548
- in third stage of labor
  - risk factors for 576
- uterine atony and 545–51
- postpartum period
  - self-harm and suicidal ideation in 381
- postpartum pre-eclampsia
  - delayed
    - defined 256–7
- postpartum thromboembolism
  - in obese women 596–7
- postpartum thyroiditis (PPT) 308



- postpartum tubal ligation 93
- post-term pregnancy 431–9
  - case scenario 431
  - clinical questions 431–6
  - defined 431
  - evaluation of 434–5
  - introduction 431
  - management of
    - algorithm for 433, **434**
    - complementary and alternative medicine approaches in 435–6
  - prenatal risks of 432, **433**
  - risk factors for 431–2, **433**
  - testing during 434–5
  - timing for delivery 432–4, **434**
- PPCM *see* peripartum cardiomyopathy (PPCM)
- PPH *see* postpartum hemorrhage (PPH)
- PPROM *see* preterm premature rupture of membranes (PPROM)
- PPT *see* postpartum thyroiditis (PPT)
- preconception care 201–11
  - aim of 201
  - background 202
  - case scenario 201
  - in chronic diseases management 203–6
  - in chronic hypertension management 204–5
  - defined 201
  - elements of 201, **208**
  - environmental toxins-related 207–8
  - introduction 201
  - medications/teratogens in 206–7, **206**
  - in morbidity and mortality prevention 205
  - for overweight and obese women 205–6
  - in pregestational diabetes management 203–4
  - rationale for 202
  - recreational drug use-related 207–8
  - substance abuse-related 207–8
- preconception counseling
  - for women with cardiac disease 268
  - for women with diabetes 203–4
- Preconception Health and Health Care Initiative of CDC 201, 202
- prednisolone
  - in HG management 230
  - during pregnancy 207
- prednisone
  - during pregnancy 207
- pre-eclampsia 255–64
  - acute glomerulonephritis *vs.* **292**
  - antiphospholipid antibodies and 257
  - atypical presentation of 256
  - clinical presentation of 255, 256
  - delayed postpartum
    - defined 256–7
  - described 255
  - diagnosis of
    - criteria in 255, **256**
  - HELLP syndrome and 256
  - hypertensive disorders of pregnancy with 257
  - low-dose aspirin in reducing risk of 257
  - maternal mortality due to 248, 255–6
  - multiple gestations and 468, **469**
  - postpartum counseling
    - CVD-related issues in 261–2
  - preterm delivery for
    - APS and 326–7
  - prevalence of 255
  - risk factors for
    - USPSTF on 257
  - with severe features
    - management of 260–1
  - superimposed
    - on pre-existing hypertension 258–9
- pre-existing hypertension 258
  - superimposed pre-eclampsia on 258–9
- pregabalin
  - for CPP 52, **53**
- pregestational diabetes
  - preconception control of 203–4
- pregestational genetic screening (PGS) in RPL 140
- pregnancy(ies) 274 *see also* pregnant women
  - abortion ending
    - prevalence of 89
  - acquired vascular lesions during
    - causes of 268
  - AED use during
    - concerns related to 316–17
    - pharmacokinetic changes related to 316
  - antiemetics in **228**, 229
  - aortopathies in 275
  - APS during
    - management of 328–9
  - ASDs in 273, 274
  - asthma during 247–53 *see also* asthma
  - BMI during 569, **571**
  - cardiac disease during
    - risk assessment models for 266–7, **266**
  - cardiomyopathy in 277–80 *see also* cardiomyopathy
  - CIN during
    - management of 193
  - CKD in 287–96, **290** *see also* chronic kidney disease (CKD), in pregnant women
  - complications of 131
    - PCOS-related 125
  - congenital aortic disease in 276
  - congenital heart disease in 273–7 *see also* congenital heart disease
  - depression during 377–84 *see also* depression
  - disorders during *see* psychiatric disease; *specific disorders, e.g., depression*
  - DM in 297–302 *see also* diabetes mellitus (DM); gestational diabetes mellitus (GDM)
  - D-transposition of great arteries in 274, 275
  - ectopic 33–47 *see also* ectopic pregnancy (EP)
  - fetal thyroid disease in 310
  - fibroids during
    - evidence-based outcomes related to 65–6, **65**, **66**

pregnancy(ies) (*continued*)

gastrointestinal disorders in *see also specific disorders and*  
     gastrointestinal disorders, in pregnancy  
 genital tract infections during  
     clinical presentations of 59  
     management of 59–60  
 heart valves during 270–1  
 hemoglobin disorders during  
     identification and management of 336–7, **337**  
 heterotopic 33–4  
 HG effects on 226  
 hypertensive disorders of 255–64 *see also* hypertensive  
     disorders of pregnancy  
 hypothyroid disease in 303–8 *see also* hypothyroid disease  
 infections in 343–54 *see also specific types and* infection(s)  
 intrahepatic cholestasis of 368, 479, 482–3  
 limiting number of  
     counseling related to 90  
 major depressive episode during  
     adverse perinatal outcomes effects on 378–9  
     non-pharmacological treatments for 379–80  
 maternal mortality during  
     causes of 248  
 medications during 206–7, 233–43 *see also specific types and*  
     medication(s), in pregnancy  
 MG effects on 320–2  
 microangiopathic disorders during 340, **340**  
 MS effects on 319–20  
 MS medications effects on 320  
 multiple 467–77 *see also* multiple pregnancies and births  
 neurologic disease in 315–24 *see also* neurologic disease  
 normal laboratory parameters in 288, 287  
 NTDs in  
     amniocentesis in detection of 220  
     MSAFP in detection of 219  
     second trimester ultrasound in detection of 219–20  
 PE during  
     work-up for 560–1, 560–3  
 physiologic changes during 233–4, 265  
     drug disposition effects 234–6, **235**  
     vs. VTE 560, **561**  
 placenta previa in 410  
 post-term 431–9 *see also* post-term pregnancy  
 with prior stillbirth 483–4  
     case scenario 483  
 pulmonary valve stenosis in 274–5  
 recreational drug use during 207–8  
 renal adaptations during 287–8, **288**  
 renal disease in  
     types of 291–2  
 seizures during 315–16  
 smoking during 207  
 spacing of  
     counseling related to 90  
 stroke in 317–19 *see also* stroke  
 target capillary glucose levels in 299, **299**  
 term 431  
 termination of 21–32 *see also* induced abortion  
     fetal anomalies and 490  
 thrombocytopenia during **339**, 339–40

thyroid function effects of 303

thyroid nodule in

    assessment of 311

TOF in 274

TPOAb in 305

unintended

    causes of 21

    during contraceptive use 91, **91**

    prevalence of 89

valvular lesions in *see* valvular lesions, during pregnancy

VSDs in 274

VTE during 355–63 *see also* venous thromboembolism (VTE)

pregnancy-induced hypertension 257

pregnancy loss

    recurrent 131–44 *see also* recurrent pregnancy loss (RPL)

pregnancy of unknown location (PUL) 38

Pregnancy Unique Quantification of Emesis (PUQE) questionnaire  
     226

pregnant women *see also* pregnancy(ies)

    self-harm and suicidal ideation among

        assessment of 381

premature birth

    defined 397

prematurity

    corticosteroids for 399–400

premenopausal women

    endometrial cancer in

        Lynch syndrome in 186

        ovarian removal in management of 184–5

        prognosis of 184–5

prenatal diagnosis 213–23

    background 213

    case scenario 213

    clinical questions 213–20

    in pregnant women at high risk for aneuploidy

        amniocentesis 218–19

        chromosome microarray analysis 219

        CVS in 218

        screening methods 213–14

    in pregnant women with low or average risk for aneuploidy

        screening methods 214–17, **214**, **215**

    second trimester genetic ultrasound in 217–18, **217**

preterm birth *see also* preterm labor

    asthma during pregnancy and 248, **248**

    fetal anomalies and 490

    neonatal morbidity and mortality due to 388, 390

    perinatal morbidity and mortality due to 385, 397

    risk factors for

        FFN in identifying 387

        TVS in diagnosis of 386–7

preterm cesarean birth

    uterine rupture related to 420

preterm delivery

    after cervical dysplasia

        risk factors for 192–3

    for pre-eclampsia or placental insufficiency

        APS and 326–7

preterm labor 385–95 *see also* preterm birth

    background 385

    case scenarios 385

- causes of 385
- clinical questions 386–92
- management of
  - non-pharmacologic strategies in 392
  - prophylactic antibiotics in 391–2
- patient at high risk for
  - management of 388, **389**
- prevalence of
  - progesterone in 387–8
- risk factors for 386, **386**
  - diagnostic tests in identifying 386–7
- spontaneous *see* spontaneous preterm labor
- tocolysis in patients presenting with 391
- preterm labor and delivery
  - in mothers of multiple gestations 469
- preterm premature rupture of membranes (PPROM) 397–406
  - background 397
  - case scenario 397
  - causes of 397
  - complications of 397–8
  - described 397
  - diagnosis of 397–9
  - management of 399–401
    - cervical cerclage and 402
    - corticosteroids in 399–400
    - before fetal viability 401–2
    - following invasive procedures 402
    - HIV and 402
    - HSV and 402
    - in latency period 399
    - magnesium sulfate in 400
    - previable 401–2
    - prophylactic antibiotics in 400
    - tocolysis in 400–1
  - prevalence of 397
  - timing of delivery in 401
- preterm-related complications
  - prevalence of 385
- primary amenorrhea
  - defined 109
  - hypergonadotropic 110–11
  - outflow tract abnormalities resulting in 110
- prochlorperazine
  - in HG management 229
- progesterone
  - in preterm labor and birth prevention 387–8
  - for unexplained RPL 137
- progesterone antagonists
  - for fibroids 68
- progesterone-containing intrauterine devices (IUDs)
  - for HMB 16–18, **17**
- progestin(s)
  - in endometriosis pain management 78
  - in PCOS management 124
- progestogen(s)
  - for HMB 15, 17
  - injected/depot
    - for HMB 18
- prolonged deceleration
  - defined **498, 499**, 500
  - physiology of 503
- promethazine
  - in HG management **228**, 229
- prophylactic antibiotics
  - in PPRom management 400
  - in preterm labor management 391–2
- propylthiouracil (PTU)
  - for Graves' disease in pregnancy 309, **310**
- prostaglandins
  - in cervical ripening **531**, 532–3
- protein C deficiency
  - during pregnancy 356, **356**, **357**
- protein S deficiency
  - during pregnancy 356, 357, **357**
- prothrombin G20210A (PGM)
  - during pregnancy 356, **356**, **357**
- psychiatric disease
  - breastfeeding by women with 380–1
  - in pregnancy 377–84 *see also* depression
    - case scenario 377
- PTU *see* propylthiouracil (PTU)
- PUL *see* pregnancy of unknown location (PUL)
- pulmonary embolism (PE) 559–65
  - case scenario 559–60
  - differential diagnosis of 560, **560**
  - general search strategy 560
  - in pregnant women
    - assessment of pretest probability for 560–2, **564**
    - diagnosis of 357–8, 358
    - maternal deaths related to 355
    - work-up for 560–1, 560–3
- Pulmonary Embolism Rule-out Criteria (PERC)
  - in assessment of pretest probability for PE during pregnancy
    - 560–2, **564**
- pulmonary regurgitation
  - maternal cardiovascular events related to 276
- pulmonary valve stenosis
  - in pregnancy 274–5
- PUQE questionnaire 226
- pure gonadal dysgenesis
  - amenorrhea related to 111
- pushing
  - during labor 572, **573**, 572, **575**
- pyridoxine
  - in HG management 229
- Quadruple Screen 216
- quadruplet(s)
  - Hellin–Zellany rule for 467
- quality metrics
  - in OVD 590
- questions
  - formulation of 3–4, **3**
- RCOG *see* Royal College of Obstetricians and Gynaecologists (RCOG)
- RDS *see* respiratory distress syndrome (RDS)
- recombinant factor VIIa (rFVIIa)
  - in PPH management 547
- recreational drug use

- recreational drug use (*continued*)
  - preconception care related to 207–8
- rectocele repair 104
- recurrent early miscarriage
  - APS and 326
- recurrent pregnancy loss (RPL) 131–44 *see also* miscarriage
  - anticoagulant therapy for 138–40, 139
  - background 131
  - $\beta$ -hCG for 135–7, 138
  - case scenario 131
  - causes of 131
  - clinical questions 131–41
  - defined 131
  - diagnostic tests for 132–4
    - confounding factors influencing proper assessment of results 137
  - EBM in 140–1
  - general search strategy 132
  - hormone supplementation for 137
  - immunotherapy for 139–40
  - incidence of 131
  - maternal risk factors for 131
  - PGS in 140
  - pregnancy after
    - serum  $\beta$ hCG measurements during 135–6
  - prevalence of 131
  - prognosis in patient in interval between pregnancies 136
  - risk factors for 133–5
  - treatment options 136–41, 138, **139, 140**
  - unexplained *see* unexplained RPL
  - uterine surgery for anomalies related to 137
- “refractory obstetric” APS
  - during pregnancy
  - management of 329–30
- regurgitation
  - pulmonary
    - maternal cardiovascular events related to 276
- Reiter’s syndrome 55–6
- relaxation therapy
  - in preterm labor management 392
- renal disease 287–96 *see also specific types, e.g.,* chronic kidney disease (CKD)
  - case scenario 287
  - introduction 287
  - in pregnancy
    - types of 291–2
- renal system
  - pregnancy-related adaptations in 287–8, **288**
    - acid-base homeostasis 288
    - anatomic changes 287
    - hemodynamic adaptations 287, **288**
    - substrate handling 287–8
- renal transplant
  - for CKD in pregnancy 293–4
- reproductive physiology
  - normal 156
- respiratory distress syndrome (RDS) 2
- restrictive cardiomyopathy 278–9
- retained products of conception
  - induced abortion and 26
- review questions
  - formulation of 3, **3**
  - studies applicable to 3, **3**
- Revised Geneva
  - in assessment of pretest probability for PE during pregnancy 561, **564**
- rFVIIa *see* recombinant factor VIIa (rFVIIa)
- Rh status
  - in women with EP 42
- “rising placenta” 408
- robotic-assisted laparoscopy
  - for fibroids 69
- ROMs *see* rupture of membranes (ROMs)
- Royal College of Obstetricians and Gynaecologists (RCOG)
  - on diagnostic tests for RPL 132
  - on ICP management 483
  - on VTE prevention during pregnancy 361
- RPL *see* recurrent pregnancy loss (RPL)
- rt-tPA *see* thrombolytic therapy with recombinant tissue plasminogen activator (rt-tPA)
- rupture of membranes (ROMs)
  - preterm premature 397–406 *see also* preterm premature rupture of membranes (PPROM)
- sacrocolpopexy
  - in pelvic organ prolapse management 103
- sacrohysteropexy
  - in pelvic organ prolapse management 103–4
- sacrospinous ligament suspension
  - in pelvic organ prolapse management 103
- safety considerations
  - OVD-related 587–9
- salpingectomy
  - in EP management 39
- salpingitis
  - chronic
    - EP and 35
- salpingostomy
  - in EP management 39–40
- “Saving Mothers’ Lives: Confidential Enquiry into Maternal Death” 563
- “Scientific Medicine” 2
- SCPE Collaborative Group *see* Surveillance of Cerebral Palsy in Europe (SCPE) Collaborative Group
- secondary amenorrhea
  - defined 109
  - hypergonadotropic 111
  - outflow tract abnormalities resulting in 110
- second stage of labor
  - ACOG on 569
  - clinical questions 571–6, 572–4, **573, 575**
  - described 571
  - length of
    - maternal age impact on 576
    - maternal outcomes related to 574–5
    - neonatal outcome related to 575–6
    - obesity effects on 576
    - maternal position effects in 572–3, **573**

- protocols and practices for 569
- vaginal delivery vs. operative delivery related to 573–4, **573**, **575**
- second trimester
  - genetic ultrasound in Trisomy 21 and Trisomy 18 detection 217–18, **217**
  - induced abortion in
    - methods of 24–5
  - screening in
    - for pregnant women with low or average risk for aneuploidy **215**, 216–17
  - termination methods in 538, **538**
  - ultrasound in NTDs detection in 219–20
- seizure(s)
  - breakthrough
    - fetal outcomes related to 316
  - medications for
    - during pregnancy 206
    - teratogenicity of 206
  - during pregnancy 315–16
    - causes of 316
    - EURAP on 315–16
    - medications for 206
- selective estrogen receptor modulators (SERMs)
  - for menopause 158–9
  - in PCOS-related infertility management 125
- selective progesterone receptor modulators (SPRMs)
  - for fibroids 68
- selective serotonin reuptake inhibitors (SSRIs)
  - during pregnancy 207
- self-harm
  - by pregnant and postpartum women
    - assessment of 381
- sentinel lymph node dissection (SLND)
  - inguinofemoral lymph node dissection vs.
    - in early-stage vulvar cancer detection 175–7, **176**
    - in vaginal cancer 177
- SERMs *see* selective estrogen receptor modulators (SERMs)
- serum  $\beta$ -human chorionic gonadotropin ( $\beta$ -hCG)
  - measurements of
    - in EP 33
    - during pregnancy after RPL 135–6
  - for patients with RPL and APS 135–7, 138
  - supplementation with 138
  - for unexplained RPL 137, 138
- sexually transmitted infections (STIs)
  - LARC methods in women with history of 92
- SF-36 Health Survey 67
- shoulder dystocia
  - cesarean delivery in prevention of 460, **460**
- single umbilical artery 488
- single vs. double layer closure
  - impact on uterine rupture 422
- sinusoidal pattern
  - defined **498**, **499**, 500–1, 501
  - physiology of 503
- SLE *see* systemic lupus erythematosus (SLE)
- sleep disturbances
  - menopause and 157
- SLND *see* sentinel lymph node dissection (SLND)
- smoking
  - contraceptive use and 92
  - EP related to 35
  - during pregnancy 207
  - vulvovaginal cancers related to 174–5
- spontaneous abortion
  - incidence of 33
- spontaneous delivery
  - AMTSL 576–7, **576**
  - background 569
  - clinical questions 570–9
  - first stage of labor 570–1, 570, **570**
  - methods for 569–81
  - second stage of labor 571–6, 572–4, **573**, **575**
  - third stage of labor 576–9, **577**, **576**, 578
- spontaneous preterm labor
  - causes of 388
  - defined 388
  - diagnosis of 385
  - patient at high risk for
    - management of 388, **389**
  - prevalence of 387–8
  - risk factors for 386–7, **386**
    - diagnostic tests in identifying 386–7
    - TVS in diagnosis of 386–7
- SPRMs *see* selective progesterone receptor modulators (SPRMs)
- squamous cell carcinoma 165
  - vulvar cancer related to 173
- SSRIs *see* selective serotonin reuptake inhibitors (SSRIs)
- sterilization 89–97
  - clinical questions 89–93
  - counseling related to 90
  - failure of 90
  - female 93
  - general search strategy 90
  - male 93–4
  - methods of 93–4
  - types of 93–4
- sterilization failure
  - risk factors for
    - counseling on 90
- stillbirth(s) 482–3
  - assessment of 480–1
  - asthma during pregnancy and 248, **248**
  - autopsy for 481–2
  - care and delivery related to 479–80
  - case scenario 479
  - defined 479
  - fetal anomalies and 490
  - fetal demise as 479
  - ICP and 483
  - introduction 479–80
  - pregnancies with prior 483–4
  - prevalence of 479
  - risk factors for 490
  - umbilical cord in 482
- Stillbirth Collaboration Network 483
- STIs *see* sexually transmitted infections (STIs)

- stress urinary incontinence (SUI)
  - pelvic organ prolapse without management of 104–5
- stripping/sweeping membranes
  - in post-term pregnancy management 436
- stroke
  - grading of evidence 319
  - during pregnancy 317–19
    - background 318
    - case scenario 317
    - clinical questions 318–19
    - management of 318–19
    - risk factors for 318
    - search strategy 319
- ST segment analysis
  - in intrapartum FHR monitoring 508
- subclinical hypothyroidism
  - later development of thyroid disease and 306–7
  - in pregnancy
    - routine screening for 307
    - T4 in 307–8
- subfertility
  - causes of 145
  - defined 145
  - unexplained 145–53 *see also* unexplained subfertility
- substance abuse
  - preconception care related to 207–8
- SUI *see* stress urinary incontinence (SUI)
- suicidal ideation
  - by pregnant and postpartum women
    - assessment of 381
- superimposed pre-eclampsia on pre-existing hypertension 258–9
- Surveillance of Cerebral Palsy in Europe (SCPE) Collaborative Group 458
- suture(s)
  - compression
    - in PPH management 549–50, 550
- systematic review processes 2–3, 3, 2
- systemic devascularization
  - in PPH management 549
- systemic lupus erythematosus (SLE)
  - hydroxychloroquine for 137
  - in pregnancy 291–2
- T4
  - for subclinical hypothyroidism in pregnancy 307–8
- tamponade
  - balloon
    - in PPH management 549
  - uterine
    - in PPH management 548–9
- team-oriented care
  - for obstetric emergencies 559–68 *see also* obstetric emergencies
- TENS *see* transcutaneous electrical nerve stimulation (TENS)
- teratogen(s) 206–7, **206**
  - most common 238, **238**
- termination of pregnancy 21–32 *see also* induced abortion
  - fetal anomalies and 490
- term pregnancy
  - defined 431
  - early 431
  - late 431
- tetralogy of Fallot (TOF)
  - in pregnancy 274
- thioamides
  - for Graves' disease in pregnancy 309, **310**
- third stage of labor 576–9, **577**, **576**, 578
  - active vs. physiological management of 576–7, **576**
  - CCT in **576**, 577
  - defined 569, 576
  - described 576
  - mean duration of 576
  - oxytocin in 576–9, **576**, 578 *see also* oxytocin, in AMTSL
  - risk of PPH in 576
  - TXA in 578
  - uterine massage in **576**, 577
- third trimester
  - polyhydramnios in
    - ultrasound in detection of 444, **444**
- thrombocytopenia
  - during pregnancy 339–40, **339**
- thromboembolism
  - postpartum
    - in obese women 596–7
  - venous *see* venous thromboembolism (VTE)
- thrombolytic therapy with recombinant tissue plasminogen activator (rt-tPA)
  - for stroke during pregnancy 318
- thrombophilia(s)
  - hereditary *see* hereditary thrombophilias
- thromboprophylaxis
  - for cesarean delivery in obese women 596–7
- thromboprophylaxis bundle
  - in VTE prevention 563–4
- thrombosis
  - APS and 327
  - deep vein 355, 357
- thymectomy
  - in prevention of MG-related complications during pregnancy 321
- thyroid disease 303–14 *see also specific types*
  - background 303–4, **304**
  - case scenario 303
  - diagnostic criteria for **304**
  - fetal 310
  - later development of
    - maternal subclinical hypothyroidism due to 306–7
  - in pregnancy
    - adverse effects of 303
- thyroid function
  - pregnancy effects on 303
- thyroiditis
  - Hashimoto's 303
  - postpartum 308
- thyroid nodule
  - in pregnancy
    - assessment of 311
- thyroid peroxidase antibodies (TPOAb)



- in pregnancy 305
- thyroid stimulating hormone (TSH)
  - in pregnancy 303–4, **304**
- thyrotoxicosis 308–11 *see also* hyperthyroid disease
  - gestational transient 226
- tocolysis
  - for bleeding placenta previa 409
  - in patients presenting with preterm labor 391
  - in PPROM management 400–1
- “To Err Is Human” 559
- TOF *see* tetralogy of Fallot (TOF)
- TOL *see* trial of labor (TOL)
- toxicity(ies)
  - fetal drug 238, **239**
- toxin(s)
  - environmental
    - preconception care related to 207–8
- TPOAb *see* thyroid peroxidase antibodies (TPOAb)
- tranexamic acid (TXA)
  - in PPH management 547
  - in third stage of labor 578
- transcervical balloon catheters
  - in cervical ripening **531**, 532
- transcutaneous electrical nerve stimulation (TENS)
  - in endometriosis pain management 79
- transplantation
  - renal
    - for CKD in pregnancy 293–4
- transvaginal ultrasound (TVS)
  - in adenomyosis evaluation 78
  - in endometriosis evaluation 77
  - in EP diagnosis 33, 36–8
  - in identifying risk factors for preterm birth 386–7
  - in low-lying placenta diagnosis 408
  - in placenta previa diagnosis 408
- trial of labor (TOL)
  - after previous cesarean birth 419
- Trial of Umbilical and Fetal Flow in Europe (TRUFFLE) 456
- trichomoniasis
  - clinical presentations of 56
  - diagnosis of 57
  - treatment of 58
- “Triple P” procedure 554
- triplet(s)
  - Hellin–Zellany rule for 467
- Trisomy 18
  - in pregnant women at high risk for aneuploidy
    - cfDNA analysis for 213–14
  - in pregnant women with low or average risk for aneuploidy
    - combined first and second trimester screening for 215–16, **215**
    - contingent screening for 216
    - first trimester combined screening for 214–15, **214**
    - second trimester screening for **215**, 216–17
    - second trimester genetic ultrasound in detection of 217–18, **217**
- Trisomy 21
  - in pregnant women at high risk for aneuploidy
    - cfDNA analysis for 213–14
  - in pregnant women with low or average risk for aneuploidy
    - combined first and second trimester screening for 215–16, **215**
    - contingent screening for 216
    - first trimester combined screening for 214–15, **214**
    - second trimester screening for **215**, 216–17
    - second trimester genetic ultrasound in detection of 217–18, **217**
- TRUFFLE *see* Trial of Umbilical and Fetal Flow in Europe (TRUFFLE)
- TSH *see* thyroid stimulating hormone (TSH)
- TTTS *see* twin–twin transfusion syndrome (TTTS)
- tubal ligation
  - postpartum 93
- tubal pathology
  - EP related to 34–5
- TVS *see* transvaginal ultrasound (TVS)
- twin(s)
  - ARTs and 467
  - congenital anomalies in 488
  - conjoined 467
  - Hellin–Zellany rule for 467
  - rare occurrence of 467
- twin–twin transfusion syndrome (TTTS) 470–2, 471
- TXA *see* tranexamic acid (TXA)
- UAE *see* uterine artery embolization (UAE)
- UFH *see* unfractionated heparin (UFH)
- UFSQOL Scale *see* Uterine Fibroid Symptom and Quality of Life (UFSQOL) Scale
- ultrasound
  - in appendicitis in pregnancy 371–2, **371**
  - in detection of perinatal outcome related to AF abnormalities 444, **444**
  - in fetal anomalies detection in pregnant patients with polyhydramnios 444–5, **445**
  - in fetal anomalies diagnostic testing 488–9
  - in NTDs detection 219–20
  - in polyhydramnios diagnosis in third trimester 444, **444**
  - second trimester genetic
    - in Trisomy 21 and Trisomy 18 detection 217–18, **217**
  - transvaginal *see* transvaginal ultrasound (TVS)
- ultrasound-assisted OVD 589–90
- umbilical artery(ies)
  - single 488
- umbilical cord
  - in stillbirth 482
- undetermined/unexplained antepartum hemorrhage (APH)
  - expectant management for 413
- unexplained infertility 145–53 *see also* unexplained subfertility
- unexplained RPL
  - aspirin for 139
  - β-hCG for 137, 138
  - cytokine modulation for 140
  - heparins for 139, 139
  - hormone supplementation for 137
  - immunotherapy for 139–40
  - uterine surgery for anomalies of 137
- unexplained subfertility 145–53



- unexplained subfertility (*continued*)
  - background 145
  - case scenario 145, 150
  - clinical questions 145–50
  - diagnosis of 145
  - general search strategy 146
  - management of 145
    - aromatase inhibitors in 147–8
    - clomiphene citrate in 146–7
    - gonadotropins in 147
    - intra-uterine insemination *vs.* other treatment options in 148–9
    - IVF *vs.* other treatment options in 149
    - laparoscopy in 149–50
    - ovarian stimulation *vs.* other treatment options in 146–8
  - prevalence of 145
  - proportion of patients who will conceive spontaneously 146
- unfractionated heparin (UFH)
  - for VTE during pregnancy 358–9
- unintended pregnancy
  - causes of 21
  - during contraceptive use 91, **91**
- unresectable locally advanced vaginal cancer
  - chemotherapy with radiation therapy *vs.* surgery for 177–8
- unresectable locally advanced vulvar cancer
  - chemotherapy with radiation therapy *vs.* surgery for 177
- urinary incontinence 101–6
  - stress *see* stress urinary incontinence (SUI)
- US Evidence-based Practice Centers (EPCs) Program 4–6
- USMEC *see* US Medical Eligibility Criteria (USMEC)
- US Medical Eligibility Criteria (USMEC)
  - of CDC 92
- US Preventive Services Task Force (USPSTF) 4–6
  - on pre-eclampsia risk factors 257
- USPSTF *see* US Preventive Services Task Force (USPSTF)
- uterine anomalies
  - as risk factor for RPL 134–5
- uterine artery embolization (UAE)
  - in adenomyosis pain management 81
  - for fibroids 68
  - in PPH management 550–1
- uterine atony
  - case scenario 545
  - PPH and 545–51
- uterine bleeding
  - abnormal *see* abnormal uterine bleeding (AUB)
  - dysfunctional 13
  - menopause and 157
- uterine dehiscence
  - defined 419
  - prevalence of 419
- uterine fibroids 63–74 *see also* fibroid(s)
- Uterine Fibroid Symptom and Quality of Life (UFSQOL) Scale 67
- uterine incision type
  - impact on uterine rupture 422
- uterine leiomyomas *see* fibroid(s)
- uterine massage
  - in third stage of labor **576**, 577
- uterine perforation
  - induced abortion and 25–6
- uterine prolapse
  - management of 102
  - pathology of 102
- uterine rupture
  - anteartum factors influencing 420
  - clinical questions 420–7
  - defined 419
  - mechanism of 419
  - obstetric history factors influencing 420
  - prediction of 427
  - risk factors for 420–2, 423–**6**
  - during TOL after previous cesarean birth
    - larger fetus effects on 421
    - maternal age effects on 420–1
- uterine tamponade
  - in PPH management 548–9
- uterosacral ligament suspension
  - in pelvic organ prolapse management 103
- uterotonics
  - in PPH management 546–7, **547**
- vaccine(s)
  - HPV
    - in CIN prevention 191–2
- vacuum aspiration
  - induced abortion by 23, 24
- vacuum delivery
  - forceps delivery *vs.* 583–4, 585
- vacuum extraction
  - at cesarean delivery
    - safety considerations 587
- vaginal birth
  - placenta previa and 410
- “Vaginal Birth After Cesarean: New Insights” 419
- vaginal birth after cesarean (VBAC) delivery 419–30
  - background 419
  - case scenario 420
  - clinical questions 420–7
  - prevalence of 419
- vaginal bleeding
  - alkaline hematin for 66
  - fibroids and 65
  - in first trimester of pregnancy 33
  - during pregnancy
    - evaluation of 337–8, **338**
- vaginal cancer 173–80 *see also* vulvovaginal cancers
  - background 173
  - case scenario 173, 178
  - causes of 174–5
  - clinical presentation of 173
  - deaths related to 173
  - general search strategy 173
  - immunosuppression and 174–5, **174**
  - incidence of 174, **174**
  - prevalence of 173
  - SLND in 177
  - unresectable locally advanced
    - chemotherapy with radiation therapy *vs.* surgery for 177–8

- vaginal closure
  - in uterine prolapse management 102–3
- vaginal delivery
  - operative 583–91 *see also* operative vaginal delivery (OVD)
  - operative delivery *vs.*
    - factors in second stage of labor determining 573–4, **573**, **575**
  - prior
    - uterine rupture related to 420
- vaginal pessaries
  - in pelvic organ prolapse management 102
- vaginal spotting
  - case scenario 33
- valacyclovir
  - for recurrent HSV infection 58, **58**
- valproate
  - during lactation 381
- valve(s)
  - artificial
    - during pregnancy 270–1
  - heart
    - during pregnancy 270–1
- valvular lesions
  - causes of 268
  - during pregnancy
    - fetal and neonatal risks associated with 271
    - labor and delivery methods related to 271
    - management of 269–70
    - maternal and obstetric risks associated with 269
    - postpartum care 272–3
- variable deceleration
  - defined **498**, **499**, 500, 501
  - physiology of 503
- varicella zoster virus (VZV)
  - in pregnancy 346–8, **347**
  - level of evidence 350
- vasa previa 413–14
  - case scenario 413
  - clinical questions 413–14
  - diagnosis of 413–14
  - prediction of 413
  - risk factors for 414
- vasectomy 93–4
- VBAC delivery *see* vaginal birth after cesarean (VBAC) delivery
- venous thromboembolism (VTE)
  - case scenario 355
  - deaths due to 560
  - imaging modalities for 561, **563**
  - introduction 355
  - management of
    - improvements in 560
  - physiologic changes in pregnancy *vs.* 560, **561**
  - during pregnancy 355–63
    - clinical questions 355–61
    - diagnosis of 357–8, 358
    - maternal deaths related to 355
    - prevention of 359–61, **360**
    - risk factors for 355–7, **356**, **357**
    - treatment of 358–9
    - women admitted to hospital 562–5
  - prevention of
    - ACCP on 359, 361
    - thromboprophylaxis bundle in 563–4
  - signs and symptoms of 560, **560**
- ventilation/perfusion scanning
  - for VTE in pregnancy 561, **563**
- ventricular septal defects (VSDs)
  - in pregnancy 274
- very low–birthweight (VLBW) infants
  - multiple pregnancies and births and 472
- vitamin(s)
  - in FGR management and prevention 457
- VLBW *see* very low–birthweight (VLBW)
- von Willebrand disease
  - bleeding in
    - management of 338–9, **338**
- VSDs *see* ventricular septal defects (VSDs)
- VTE *see* venous thromboembolism (VTE)
- vulvar cancer 173–80 *see also* vulvovaginal cancers
  - background 173
  - case scenario 173, 178
  - causes of 174–5
  - clinical presentation of 173
  - clinical questions 174–8
  - deaths related to 173
  - early-stage
    - CIL in management of 175–6
    - SLND *vs.* inguinofemoral lymph node dissection in detection of 175–7, **176**
  - general search strategy 173
  - immunosuppression and 174–5, **174**
  - incidence of 174, **174**
  - prevalence of 173
  - squamous cell carcinoma and 173
  - symptoms of 173
  - unresectable locally advanced
    - chemotherapy with radiation therapy *vs.* surgery for 177
- vulvovaginal cancers
  - HPV and 174–5
  - periinvasive and invasive
    - immunosuppression and 174–5, **174**
    - incidence of 174, **174**
- VZV *see* varicella zoster virus (VZV)
- warfarin
  - fetal effects of 238, **239**, **238**
  - during pregnancy 206
  - for VTE during pregnancy 359
- wart(s)
  - genital 56–9
- weight
  - fetal
    - measurements of 451
    - measurements of 451
- weight reduction
  - in PCOS–related infertility management 125
- well-being
  - fetal
    - in post-term pregnancy 434–5

Wells Criteria

- in assessment of pretest probability for PE during pregnancy 561–2, **564**

White classification

- for DM in pregnancy 297, **298**

WHO *see* World Health Organization (WHO)

women of reproductive age

- CPP in musculo-skeletal abnormalities with 51

World Health Organization (WHO)

- classification system on cardiac disease 267

ZAHARA risk prediction score

- for cardiac event during pregnancy 266–7, **266**

Zaki labor duration

- maternal age in **571**

zygosity

- determination of 467–8
- placental arrangement *vs.* 467

zygotic splitting

- following ARTs 467